



LUND UNIVERSITY

Liver metastases from colorectal cancer. Different strategies and outcomes

Valdimarsson, Valentinus

2019

Document Version:

Publisher's PDF, also known as Version of record

[Link to publication](#)

Citation for published version (APA):

Valdimarsson, V. (2019). *Liver metastases from colorectal cancer. Different strategies and outcomes*. [Doctoral Thesis (compilation), Department of Clinical Sciences, Lund]. Lund University, Faculty of Medicine.

Total number of authors:

1

Creative Commons License:

Unspecified

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

Liver metastases from colorectal cancer

Different strategies and outcomes

Valentinus Valdimarsson



LUND
UNIVERSITY

DOCTORAL DISSERTATION

by due permission of the Faculty of Medicine, Lund University,
Sweden.

To be defended at Segerfalksalen, BMC, Sölvegatan 19, Lund, on
December 13th, 2019, at 13.00.

Faculty opponent

Bjørn Atle Bjørnbeth, Oslo University Hospital, Oslo, Norway.

Organization LUND UNIVERSITY Department of Clinical Sciences Author: Valentinus Valdimarsson	Document name Doctoral Dissertation	
	Date of issue 2019-11-21	
	Sponsoring organization	
Title and subtitle: Liver metastases from colorectal cancer - Different strategies and outcomes		
Abstract Patients with colorectal liver metastases (CRLM) increasingly undergo liver resections. The belief is that the resection or ablation of a tumor, when possible, is the only possibility of a cure. The classical strategy is where the primary colorectal tumor is resected as the first intervention, followed by resection of the liver metastasis at a second stage. The liver-first strategy is where preoperative chemotherapy is given, followed by resection of the liver metastases and then resection of the colorectal primary tumor at a second stage. The third option is the simultaneous strategy where the patient undergoes both liver and primary tumor resection during the same operation. The patient selection and drop-out from the planned intervention are poorly known. None of the three strategies have demonstrated any clear advantage or disadvantage in terms of survival. A repeated hepatectomy, for patients with recurrent CRLM, is increasingly performed with mostly unknown postoperative functional liver volume (FLV). Specific aims to investigate: <ol style="list-style-type: none"> I. Why do patients scheduled for the liver-first strategy not complete both the planned liver and primary resections? II. Compare the liver-first to the classical strategy for patients presenting with synchronous CRLM (sCRLM). III. Compare the simultaneous strategy with the classical strategy for patients presenting with sCRLM, focusing on patients undergoing major liver resections. IV. Measure liver regeneration and survival data after a repeated liver procedure (resection or ablation) for recurrent CRLM. Results and conclusions: <ol style="list-style-type: none"> I. Up to 35% of patients with sCRLM do not complete the planned treatment. II. The liver-first and the classical strategy did not show any overall survival difference. III. Simultaneous resections appeared to have more complications, shorter total length-of-stay but similar overall survival as patients chosen for the classical strategy. IV. We found a small change in FLV after two hepatic procedures but with a considerable inter-individual variation. Patients selected for a repeated hepatic procedure for recurrent CRLM had an acceptable survival. When choosing different strategies for sCRLM patients, our results imply that we should select according to treatment logistics, tumor symptoms, and surgical feasibility. When patients present with recurrent CRLM, a high variance in liver volume after repeated resection can be expected when planning future repeated resections.		
Keywords: Secondary liver neoplasms, colorectal neoplasms, hepatectomy, mortality, treatment outcome, retrospective studies, Sweden, registries, functional liver volume, repeat hepatectomy.		
A classification system and/or index terms (if any)		
Supplementary bibliographical information: Lund University, Faculty of Medicine Doctoral Dissertation Series 2019:122		Language: English
ISSN: 1652-8220		ISBN: 978-91-7619-851-3
Recipient's notes	Number of pages: 72	Price
	Security classification	

I, the undersigned, being the copyright owner of the abstract of the above-mentioned dissertation, hereby grant to all reference sources permission to publish and disseminate the abstract of the above-mentioned dissertation.

Signature

Date 2019-11-07

Liver metastases from colorectal cancer

Different strategies and outcomes

Valentinus Valdimarsson



LUND
UNIVERSITY

Copyright: Valentinus Thor Valdimarsson
E-mail: valentinus.valdimarsson@med.lu.se

The cover photo is from the 1967 publication by Flanagan and Foster¹, with permission from the publisher Elsevier

Department of Clinical Sciences, Division V
Faculty of Medicine, Lund University

ISBN 978-91-7619-851-3
ISSN 1652-8220

Printed in Sweden by Media-Tryck, Lund University
Lund 2019



Media-Tryck is an environmentally certified and ISO 14001:2015 certified provider of printed material. Read more about our environmental work at www.mediatryck.lu.se

MADE IN SWEDEN 

To

*Erla Þóra
Guðjón Ari
Ármann Óli*

“Normal science, the activity in which most scientists inevitably spend almost all their time, is predicated on the assumption that the scientific community knows what the world is like.”

— Thomas S. Kuhn, *The Structure of Scientific Revolutions*

Table of Contents

- LIST OF PAPERS..... 8**
- THESIS AT A GLANCE..... 9**
- ABBREVIATIONS 10**
- INTRODUCTION 12**
 - CANCER 12
 - METASTATIC CANCER DISEASE..... 14
 - EPIDEMIOLOGY OF COLORECTAL CANCER AND COLORECTAL LIVER METASTASES 16
 - THE HISTORY OF METASTATIC LIVER SURGERY 18
 - DIFFERENT APPROACHES TO COLORECTAL LIVER METASTASES 19
 - RISK SCORES..... 21
 - LIVER VOLUME MEASUREMENTS 22
 - LIVER REGENERATION 24
 - STRATEGIES TO INCREASE THE RESECTABILITY OF THE LIVER 25
 - DIFFERENT STRATEGIES FOR SYNCHRONOUS CRLM (sCRLM)..... 26
 - REPEATED RESECTIONS..... 28
 - REGISTRY STUDIES 29
 - SELECTION..... 30
- AIMS AND OBJECTIVES 32**
- MATERIALS AND METHODS..... 33**
 - Paper I* 33
 - Paper II and III*..... 33
 - Paper IV*..... 34
- PROJECT DESIGN..... 36**
 - Paper I* 36
 - Paper II and III*..... 36
 - Paper IV*..... 36
- STATISTICAL ANALYSIS..... 37**
- ETHICS 38**

RESULTS.....	39
<i>Main findings in paper I.....</i>	<i>39</i>
<i>Main findings in paper II.....</i>	<i>41</i>
<i>Main findings in paper III.....</i>	<i>43</i>
<i>Main findings in paper IV.....</i>	<i>45</i>
GENERAL DISCUSSION	47
<i>Paper I.....</i>	<i>47</i>
<i>Paper II.....</i>	<i>48</i>
<i>Paper III.....</i>	<i>49</i>
<i>Paper IV.....</i>	<i>50</i>
CONCLUSIONS	52
FUTURE CHALLENGES	53
POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ SVENSKA	55
VÍSINDALEG SAMANTEKT Á ÍSLENSKU	58
ERRATA.....	61
ACKNOWLEDGMENTS.....	62
REFERENCES	63

List of papers

The basis for this thesis is the following papers, which will be referred to by their roman numerals I-IV:

- I. Sturesson C, **Valdimarsson VT**, Blomstrand E, Eriksson S, Nilsson JH, Syk I and Lindell G. Liver-first strategy for synchronous colorectal liver metastases – an intention-to-treat analysis. *Hpb*. International Hepato-Pancreato-Biliary Association Inc.; 2017;19:1–7.
- II. **Valdimarsson VT**, Syk I, Lindell G, Norén A, Isaksson B, Sandström P, Rizell M, Ardnor B, Sturesson C. Outcomes of liver-first strategy and classical strategy for synchronous colorectal liver metastases in Sweden. *Hpb*. International Hepato-Pancreato-Biliary Association Inc.; 2018;20(5):441-447.
- III. **Valdimarsson VT**, Syk I, Lindell G, Sandström P, Isaksson B, Rizell M, Norén A, Ardnor B, Sturesson C. Outcomes of simultaneous resections and classical strategy for synchronous colorectal liver metastases in Sweden. A nation- wide study with special reference to major liver resections. Paper submitted.
- IV. **Valdimarsson VT**, Hellberg K, Brismar TB, Sparrelid E, Sturesson C. Repeat procedures for recurrent colorectal liver metastases: analysis of long-term liver regeneration and outcome. *Cancer Management and Research*. 2019; 11:2617—2622.

The reproductions of the complete papers are with the kind permission of the publishers.

Thesis at a glance

	QUESTION	METHODS	RESULTS AND CONCLUSIONS
I	Why patients scheduled for the liver-first strategy do not complete both liver and primary resections?	A retrospective analysis of 176 patients with CRLM, from 2011 to 2015, referred to multidisciplinary meetings at one liver surgery institution.	Twenty-six patients (35%) abandoned planned treatment in the liver-first and ten patients (29%) in the classical group (NS). The most common reason for failure was disease progression.
II	What is the difference in patient outcomes when comparing the liver-first and the classical strategy for patients presenting with sCRLM?	Prospective national registry analyses from 2008 to 2015. Six-hundred-twenty-three patients underwent a liver-first or classical strategy.	The classical strategy group had more T4 primary tumors and node-positive primaries — no 5-year OS difference was found between groups. A majority of patients with rectal primaries were in the liver-first group.
III	What is the difference in patient outcomes when comparing the simultaneous and the classical strategy for patients presenting with sCRLM?	A prospective national registry analyses, from 2008 to 2015. We identified 537 patients that underwent a simultaneous and classical strategy.	Patients in the simultaneous strategy group were less likely to have a rectal primary (22% vs. 31%) and to undergo a major-liver resection (16% vs. 41%), had a shorter total hospital length-of-stay (11 vs. 15 days) but more complications (52% vs. 36%) — no 5-year OS difference was found between groups.
IV	What is the survival, and how is the liver regenerating after a repeated hepatic procedure (resection or ablation) for recurrent CRLM?	Retrospective analyses of 82 patients, between 2005 and 2015. We examined patients with recurrent CRLM from two liver surgery institutions. The liver volume was calculated before the first procedure and before and after the second procedure.	The measured FLV was 1438 (1204–1896) ml after the first procedure and 1470 (1172–1699) ml after the repeated procedure. Ten patients (12%) had a residual volume of less than 75% of the initial liver volume. The 5-year OS was 37 (26–54) % after the repeated procedure.

Abbreviations: CRLM – Colorectal Liver Metastases, sCRLM – Synchronous Colorectal Liver Metastases, SCRCR - Swedish Colorectal Cancer registry, SweLiv - the National Quality Registry for Liver and Biliary Cancer, OS – Overall Survival, NS – Not Significant, FLV – Functional Liver Volume.

Abbreviations

ALPPS	Associating Liver Partition and Portal vein ligation for staged hepatectomy
ASA	American Society of Anesthesiologists
AUC	Area Under the Curve
BMI	Body Mass Index
BSA	Body Surface Area
CEA	Carcino-Embryonic Antigen
CI	Confidence Interval
Cox ph	Cox proportional hazard
CRLM	Colorectal Liver Metastases
CT	Computed Tomography
CTP	Child-Turcotte-Pugh
FLV	Functional Liver Volume
HR	Hazard Ratio
ICG	Indocyanine Green
INR	International Normalized Ratio
IQR	Interquartile Range
mCRLM	Metachronous Colo-Rectal Liver Metastases
MDCT	Multi-Detector Computed Tomography
MDT	Multi-Disciplinary Team
MELD	Model for End-stage Liver Disease

MRI	Magnetic Resonance Imaging
OR	Odds ratio
OS	Overall Survival
PHLF	Post-Hepatectomy Liver Failure
PVE	Porta Vein Embolization
PVL	Portal Vein Ligation
RBS	Register Based Study
RFA	Radio-Frequency Ablation
SCRCR	Swedish Colorectal Cancer registry
sCRLM	Synchronous Colorectal Liver Metastases
SweLiv	National Quality Registry for Liver and Biliary cancer
TBS	Tumor Burden Score
TELV	Total Estimated Liver Volume
TSH	Two-Stage Hepatectomy

Introduction

Cancer

Cancer has been known to man for a surprisingly long time, with the earliest records dating back to approximately 3000 BC². A tumor resembles a moving crab with its many limbs that stretch outward from a central body, and therefore the word cancer in Latin literally means a crab, as is seen in the astrological sign for cancer³. The disease is widespread, and every person has about a 40% risk of being diagnosed with cancer during one's lifetime⁴. The beginning of cancer or tumorigenesis is a multi-rate-limiting process where the disease starts with a disruption in one cell that, against all odds, overcomes numerous obstacles to multiply and maintain itself. A tumor that comprises many cancer cells is a complex tissue with a metastatic potential that can come early or late during the cancer developmental process⁵. It appears that this process is similar for most, if not all, cancer forms in the human body and the processes that are assumed important are⁶:

1. The sustained proliferation process, e.g., disruption in autocrine, or downstream signal pathways (e.g., a mutation in the RAS proliferation genes).
2. The growth suppression avoidance process, e.g., disruption in growth-and-division (e.g., RB gene mutation), or apoptosis signaling failing (e.g., TP53 gene mutation).
3. The cell-death-resistance process, e.g., disruption in cell death regulation (e.g., Bcl-2 gene mutation).
4. The replicative-immortality process, e.g., disruption in telomerase functions.
5. The angiogenesis induction process, e.g., a mutation in the vascular endothelial growth factor-A (VEGF-A) or the thrombospondin-1 (TSP-1) genes.

6. The activation of invasion and metastases process, e.g., E-caderin or matrix-degrading-enzymes disruption.
7. The genome instability and mutation acquisition process, e.g., epigenetic mechanisms such as DNA methylation and histone modification.
8. The inflammation promotion process, e.g., tumor-promoting effects of immune cells.
9. The energy metabolism reprogramming process, e.g., upregulation of the glucose transporters.
10. The immune destruction avoidance process. e.g., paralyzing infiltrating immune cells by secreting immunosuppressive factors.




Figure 1. Parallel Pathways of tumorigenesis and treatment targets⁶. With permission from the publisher, Elsevier.

In summary, many different oncogenes are known to cause cancer and are essential in the formation and evolution of the disease. The sequence or order

of the processes happens differently between patients, cancer types, and subtypes.

Metastatic cancer disease

The ability of cancer cells to metastasize has long been known, and in 1889 Stephen Paget published the “seed and soil” hypothesis where tumor cells from the primary tumor (“seed”) move to a favorable distal organ (“soil”)⁷. Metastatic cancer disease is the most common cause of death for patients with cancer and accounts for approximately 90% of cancer deaths^{7,8}. It has often been thought that cancer first spreads to the lymphatic tissue and later distally, which was the basis of the widely used TNM classification system⁹. How does a local tumor evolve into disseminated cancer with colonies to different organs, and does it happen in a particular fashion with the same subtypes of cancer occupying the same organ first?

The earliest modern paradigm of metastatic cancer comes from the father of modern surgery, William S. Halsted (1852-1922), that put forth his well-known paradigm at the beginning of the last century. The Halstead paradigm predicts that most cancers follow a predictable pattern of dissemination from one to the next echelon, i.e., from invasive cancer to local lymph nodes, and finally to distant organs¹⁰. The view at the time was that patients who developed distant metastases had an incurable disease, and palliation was the only available treatment. During the 1930s, physicians began to question that paradigm¹¹ and more and more treatment options emerged, which offered acceptable survival for patients selected for metastatic surgery¹². The goal was to stop cancer spreading by systemically resecting the local tumor and metastatic colonies before it was technically impossible, and the disease considered incurable.

Different from the Halstead paradigm, we have the systemic paradigm, sometimes named the Fisher paradigm, from the 1960s. This paradigm states that metastatic cancer is a systemic disease where cancer has metastatic potential at any time, and multiple metastases can exist without being macroscopically detectable, i.e., occult metastases¹³.

The spectrum paradigm emerged in the 1990s and states that cancer diseases can have different biological metastatic spectrums¹⁴. In the spectrum paradigm, a patient has only local invasive primary at one end of the spectrum, but at the

other end of the spectrum, patients are diagnosed early with multiple distant metastases. Furthermore, there is an intermediate state called the oligometastatic state, where only a few or only one resectable metastasis exists at a given time. These oligometastases can then give rise to distant metastases, and therefore a resection could be potentially curable^{11,13,14}.




Figure 2.

Tumor metastases cascade is a complicated process where a tumor cell needs to invade with intravasation and evade to establishes distant colonies that can grow, die off or stay dormant — published under the terms of the Creative Commons CC-BY license⁷.

What is currently known from the biology of the metastatic process? As stated above, the metastatic cascade can start at any time during the tumor process and is categorized as local tumor intravasation, circulation survival, and finally extravasation to the distal organ, shown in figure 2⁷. In order to disseminate from the primary tumor, the tumor cell needs to change its shape, brake away from neighboring cells, and finally use other cells, e.g., tumor-associated-macrophages and fibroblasts to invade the basal membrane and disseminate to the circulation with a mechanism called the epithelial-mesenchymal-transition (EMT). In the circulation, the tumor cell needs to survive and hide from the immune system, and finally, extravasate from the circulation to a distant organ.

There, the microenvironment is often hostile, and both the microenvironment and the tumor cells need to adapt in order for the cells to survive. In the distal organ, the invasive micrometastatic cells can die, form macrometastatic colonies, or go into a dormant state because of stress, hypoxemia, nutrition deficiency, or the immune response^{6-8,15-17}. The dormant state can last many years or up to decades⁷. Metastases can follow the usual lymphatic or hematogenous pathways but even spread directly through body cavities, with different oncogenes responsible for different routes¹⁶.

Metastatic potential is related to the tumor size and proliferation rate, where larger tumors with more cell divisions represent a higher likelihood of metastases^{5,18}. A tumor needs to be under 2.7 +/- 1.6 mm, in order to decrease a five-year discoverable metastases risk from nine to one percent¹⁵. Small local tumors can thus give rise to distant metastases, with about 20-30% of patients with lymph node-negative cancer developing distant metastases¹⁶, and about 65% of local-only cancer patients having circulating cancer cells in the bloodstream during surgery¹⁸. Metastatic potential varies as well between different tumor cells within the same tumor^{9,17}, and in about 65% of patients, lymphatic and distant metastases originated from independent sub-clones within the same primary tumor⁹. Therefore, many biological different sub-clones can exist in various places in the body at the same time⁹. The metastases can then, by themselves, metastasize back to the primary tumor site or other organs^{6,16}. Many different oncogenes have as well been linked to metastatic potential, worse survival, and risks for cancer recurrence^{11,19}.

We have gotten better in our understanding of cancer behavior and biology during the last 130 years since Halsted and Paget. We are even closer in our understanding of what constitutes metastatic cancer, and which paradigm is correct.

Epidemiology of colorectal cancer and colorectal liver metastases

Colorectal cancer is the third most common cancer for each gender²⁰, and in the year 2017, about 4,400 patients were diagnosed with colon cancer and approximately 2,100 with rectal cancer in Sweden. The age-standardized incidence of colorectal cancer has been stable since the beginning of this century, with 31.2 per 100,000 for males 24.9 per 100,000 for females^{21,22}. The

older generation is affected more, with the median age at diagnosis being 72 years for males and 70 years for females, and only around five percent are below the age of fifty²³. Survival for patients diagnosed with metastatic colorectal cancer has steadily increased during the last decades^{20,24,25}, with a relative 5-year survival of 66% for colon cancer and 68% for rectal cancer²⁶. In Sweden, age-standardized mortality has declined for colon cancer but has been fairly constant for rectal cancer during the last decades, as seen in figure 3^{20,22,23}.




Figure 3A. The age-standardized incidence and mortality rates (number of new cases per 100 000 persons per year) for colon cancer in Sweden²².




Figure 3B. The age-standardized incidence and mortality rates (number of new cases per 100 000 persons per year) for rectal cancer in Sweden²².

About 20% present with a distal metastasis, stage IV disease, at diagnosis, and a further 20 % will be diagnosed later with metastatic disease²⁷. Metastases to the liver are the most common distant metastases from colorectal cancers, 40-70% of all metastases, followed by lung metastases^{23,27,28}. About 15-20% of patients with colorectal cancer have liver metastases at the time of diagnosis of the primary cancer, called synchronous liver metastases (sCRLM), and another 15% develop metastases later, metachronous CRLM (mCRLM)^{23,28-30}. Approximately 2000 patients are diagnosed with CRLM each year in Sweden^{21,28}.

The history of metastatic liver surgery

Partial hepatectomies for patients with metastatic tumors have been performed for over 80 years, with one of the earliest reports from the year 1935 by the surgeon Werner Möller. Möller and his colleagues performed a partial hepatectomy on a 29-year-old woman, previously resected for ovarian cancer. The patient recovered well, could return to work³¹, and was alive and well six years after the liver resection¹.




Figure 4.
The line of resection of the right lobe ¹. With permission from the publisher, Elsevier.

In the year 1967, Flanagan and Foster analyzed seventy-two patients that had undergone hepatic resection for metastatic cancer. They found a 24% (twelve patients) five-year survival, that increased to 39% for those with solitary metastasis. The authors thus suggested aggressive surgical treatment of metastatic cancer for patients with treatable primary tumors and adequate physiologic reserve¹.

Different approaches to colorectal liver metastases

How do we remove liver metastases? Liver tumor resection is usually done by removing one or more wedges or a portion of the liver with a resection done by anatomical landmarks. These landmarks are divided by the portal veins into segments, called the Couinaud's segments³², shown in figure 5.




Figure 5. Liver anatomy divided by Couinaud's segments³³. RHV. Right hepatic vein, LHV. Left hepatic vein, MHV. Middle hepatic vein, IVC. Inferior vena cava, PV. Portal vein. With permission from the publisher, Elsevier.

Removal of three or more segments is usually defined as a major resection³⁴⁻³⁶. A resection is usually done with an open subcostal Kocher laparotomy or by a laparoscopic resection, that has recently gained popularity.

A comparison between an open resection and laparoscopy can be difficult because of reported conversion rate to open procedure, but the laparoscopic approach appears to be a safe alternative to open surgery, and it appears to have better results in terms of complications and hospital length-of-stay, without significant difference in long-term mortality and cancer recurrence^{37,38}.

Patients too sick to undergo an operation or having technically challenging liver tumors are nowadays often offered destructive, ablative treatment, instead of or together with a resection³⁹. The ablation is usually done with a needle that transmits the destructive force and is usually performed with either radiofrequency or microwave heating, or using electrical, chemoembolization, ultrasonic, laser, ethanol, or freezing destruction⁴⁰. The ablation can be applied endoscopically, percutaneously, during laparoscopic surgery, or directly during open surgery. The technique is rapidly evolving, and newer ablative procedures can be applied for more and larger tumors with greater precision^{39,40}. Because an ablation is often selected for sicker patients with more difficult tumors, a comparison is difficult, but the technique has generally shorter length-of-stay, fewer complications, but worse overall survival and higher local recurrences^{39,41-43}. One multicenter phase II study randomized 119 patients with inoperable CRLM to a surgery-ablation arm or a systemic-chemotherapy arm. The study had unfortunate limitations with small sample size, a difference in the number of metastases, and unintended cross-over to the surgical-ablation arm. However, the authors found similar overall survival and progress free survival during the first three years, but after the three years, resection-ablation appeared to have survival benefits⁴⁴.

Another approach for patients not able to undergo liver resection due to the metastatic burden in the liver or liver failure is a total resection of the whole liver and transplantation of a tumor-free liver from a donor. Two of the seven first documented patients to undergo liver transplantation had CRLM disease, with the first patient dying on the eleventh day postoperatively and the second dying intraoperatively⁴⁵. Liver transplantation for CRLM has been highly controversial because of the need for immunosuppressive medications, tumor biology, and a shortage of donor organs. A systemic review on the subject, published by Moris et al. in 2017, showed a heterogenous group of only 66 patients from 11 studies with 5-year survival ranging from 12% to 60%, and 61% having a recurrence within one year⁴⁶. A recent prospective study showed a remarkable high 5-year survival of 83%, with a median follow-up of only 36 months, and 53% recurrence. The author suggested that better survival was perhaps due to superior tumor biology⁴⁷.

Risk scores

Have we developed adequate scores or criteria for which patients should undergo liver resections, and which should definitely not? Finding different score systems should be a priority in order to standardize, make the process more transparent, and learning how to best follow-up patients after liver resections.

At many hospitals, a multidisciplinary team decides which patients shall undergo liver resection, but how many patients with colorectal cancer will ultimately undergo liver resection? The difference between individual hospitals varies a lot, with a range of 0.7 to 6.8% of all patients with colorectal cancer undergoing liver resections⁴⁸. The probable reason for this difference is that hospitals have different official and unofficial criteria, traditions, and skills. Does the difference in hospital resection rate and selection explain the vast difference in published survival data, with a reported 5-year survival ranging from 16 to 74%, and a 10-year survival ranging from 9 to 69% with an overall median survival of 3.6 years⁴⁸⁻⁵⁰?

The most widely used risk score is the Fong score that includes five different parameters: nodal status, CRLM timing (sCRLM or mCRLM), carcinoembryonic antigen (CEA) level, largest CRLM size, and CRLM number⁵¹. The score was based on uni- and multivariate-analysis and found a 5-year survival of 60% for the “best” group and 14% for the “worst” group⁵¹. Sasaki et al. tried to find a simpler score to predict long-term survival using an example from a previously known hepatocellular carcinoma score. The score is called the tumor burden score (TBS), with the formula: $TBS^2 = d^2 + n^2$, where d is the largest diameter of CRLM, and n is the number of CRLM metastases. The TBS had a slightly higher area under the curve (AUC) of 0.669 compared to the maximum tumor size (AUC 0.619) and the number of tumors (AUC 0.595) for predicting overall survival ($P=0.012$ and <0.001). The TBS could then be divided into three zones: zone 1 ($TBS < 3$), zone 2 ($TBS \geq 3$ and < 9) and zone 3 ($TBS \geq 9$). As TBS increased, survival declined (5-year OS: zone 1, zone 2, and zone 3—68.9%, 49.4%, and 25.5%, respectively; $P < 0.001$)⁵². The authors did external validation for the TBS, but others have not validated the score. Roberts et al. compared seven different score systems for CRLM and found them to be “reasonable” at best with only one score exceeding 0.7 in C-statistic for predicting three-year disease-specific survival⁵³.

Are bleak scores simply proxies for more aggressive cancer biology? The role of different score systems is yet to be entirely determined. Hopefully, a more powerful computation, e.g., machine learning and neural networks, can help make better risk scores. Additionally, a better understanding of different tumor behaviors and biologies should enable superior outcome predictions, selections, and follow-up approaches for patients with CRLM.

Liver volume measurements

How do we minimize the risk of postoperative liver failure following liver metastatic surgery? How do we measure liver volume? How much liver can we remove, and can we measure liver function?

Post-hepatectomy liver failure (PHLF) is a life-threatening condition and the major cause of death related to liver resections. The International Study Group of Liver Surgery (ISGLS) defines PHLF as an increase in international normalized ratio (INR) and hyperbilirubinemia on or after postoperative day five, subclassified into three severity grades. We can minimize PHLF risk with a careful preoperative assessment of liver-health and the planned postoperative liver size⁵⁴.

Unfortunately, we are not able to measure liver function directly, but several methods can be used to assess liver health indirectly. All physicians are familiar with the clinical hallmarks and standard blood tests to measure liver injury and function. The most common clinical signs associated with liver injury are ascites and liver encephalopathy, and frequently used blood tests are: albumin, liver transaminases, INR, and bilirubin^{54,55}. The famous Child-Turcotte-Pugh (CTP)⁵⁶ and later, the model for end-stage liver disease (MELD) scores have been used for predicting prognosis and the need for liver transplantations for patients with liver cirrhosis⁵⁷. These scores are also often used when predicting complications after liver surgery with age, the CTP score, and the American Society of Anesthesiologists (ASA) score having a better prediction for complications than the MELD score⁵⁷. Standard diagnostic imaging can additionally be useful for observing liver injury, such as hepatic steatosis, with MRI and magnetic resonance spectroscopy (MRS) having the best diagnostic accuracy⁵⁸. Other more specified tests are: - quantitative metabolic tests that measure metabolic function, - Indocyanine Green (ICG) retention test that measures hepatic perfusion, and - scintigraphy

that measures functional hepatocyte mass. A lower metabolite elimination rate, increased ICG retention, and decrease scintigraphy uptake are related to increased risk of liver failure⁵⁵.

How much of a healthy liver can we remove, and how little can we safely leave behind? With the remaining liver being too small, the patient risks having postoperative liver failure. About 20-27% of residual liver volume for a preoperative healthy liver and 30-50% residual liver volume for an injured liver appears to be safe^{59,60}. Additionally, a postoperative liver volume to body weight ratio larger than $\geq 0.5\%$ is reported to be sufficient⁶¹.

How do we assess preoperative liver volume in order to know how much of the liver we can resect? The liver is related to our size and grows from 0.072 – 0.16 liters in infancy to 0.81 - 1.7 liters in adolescents⁶². During the last decades, we have seen an increase in the use and availability of imaging, e.g., computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US)⁶³. We also have better computer and software power that has made liver volume calculations more precise and faster. Usually, the liver volume imaging measurement is done manually or automatically by tracing the liver outline with a cursor on an image slice. The area is calculated, superiorly to inferiorly, with 0.5 or 1.0 cm interval between slices, shown in figure 6. The sum of the calculated areas gives us the total liver volume.




Figure 6.

Liver area calculation marked with a green line, with permission from the publisher John Wiley and Sons⁶⁴.

Niehues et al. compared liver measurement by using an in-vivo CT volumetric measurements compared to an ex-vivo water displacement volumetry in eleven pigs. The authors found a high correlation, with a coefficient of determination, r^2 0.985 ($p < 0.0001$), and a median 13% higher in-vivo liver volume, most likely caused by the in-vivo blood perfusion⁶⁵. Sonnemans et al. compared liver volume weight in cadavers to pre-death CT volumetric measurements and found the coefficient of determination, r^2 , to be 0.90 ($P < 0.001$)⁶⁶. Different formulas have been computed in order to calculate the volume instead of measuring it. Because the liver follows the body surface area (BSA) quite closely, i.e., weight and height, many formulas use BSA. One of the most used formulae was published by Vauthey et al., where the authors used a regression analysis to establish the formula: TLV (total liver volume) = $-794.41 + 1,267.28 \times \text{BSA}$. However, the coefficient of determination was only 0.46 ($p < 0.0001$) when compared to CT measured liver volume⁶⁷.

To date, no ideal test is available to test the liver function or volume, and many factors need evaluation, with the most crucial thing being the liver health and the planned postoperative volume. We can conclude that volumetric image measurements are fairly accurate and can be used when measuring liver volumes. Hopefully, we will be able to make better predictions, perhaps by combining both volumetric and functional measurements in the near future.

Liver regeneration

All of us have witnessed the regenerative potential of the body, most often in the form of wound healing. The ancient Greeks knew of the liver regenerative potential, and in the year 1931, Higgins and Anderson observed that after surgical removal of two-thirds of the liver, it grows back to its original volume after about week^{68,69}. Under the usual condition, a healthy hepatocyte rarely divides and stays in the G0 phase, but during drug, mechanical, or infectious related injury, the liver can regenerate itself⁶⁸. Transplantation of a limited number of hepatocytes from a healthy mouse to a liver depleted mouse can be enough for it to survive, with the regenerative potential equal to that of the bone marrow⁷⁰. The regenerative potential of liver hepatocytes appears to decrease with age, but it appears that all types of liver cells have the potential to regenerate, and a small stem cell population (oval cells) can even generate different types of cells^{70,71}. After liver resection, the activation signal for the liver cells is believed to come from shear stress with the release of nitric oxide

(NO), prostaglandins (PGs), cytokines, and growth factors before angiogenesis, and extracellular matrix breakdown follows^{68,71}. The regeneration potential appears to be related to the size of injury or resection with the largest liver resection delivering the largest regeneration potential^{35,71,72}. The growth factors and cytokines that are involved in the regeneration process have been shown to stimulate residual micrometastases after liver resection in rodents⁷¹. The human liver regeneration potential after resection is multifactorial, and a lot is still unknown⁶⁸.

The liver regeneration potential has been evaluated to be around 80-92% of the preoperative volume^{34,35,73}, which can be influenced by age, cirrhosis, chemotherapy, and the size of the liver resection^{34,72}. A repeated resection appears to have roughly the same effect on liver regeneration even though this is inadequately examined⁷³. One of the aims of the thesis was to evaluate the regenerative potential after repeated liver resection.

Strategies to increase the resectability of the liver

The reasons patients usually do not undergo liver resections for CRLM are frailty, unresectability, dissemination beyond the liver, or that the extent of the metastases in the liver are too great for the remaining liver to be able to function. For a number of patients, chemotherapy can decrease the size and number of the liver metastases, enabling the patients to undergo liver resection at a later stage, with up to 50% of originally unresectable patients being later considered for liver surgery after chemotherapy⁷⁴.

The liver has a remarkable ability to regenerate, as stated above. For over forty years, we have known that occlusion of either the right or left branch of the portal vein can result in substantial liver regeneration, first with open surgical ligation, and later with percutaneous transhepatic portal vein embolization (PVE) which is as safe and as effective as ligation^{60,75,76}.

At the beginning of this century, Adam et al. reported two-staged hepatectomies (TSH) for CRLM in both liver lobes. There the authors performed a partial resection of the liver, allowed the liver to regenerate for 4-6 weeks, and then performed a second resection⁷⁷. Later, a portal vein ligation or PVE was integrated into the staged hepatectomies, often also referred to as TSH⁶⁰. At the beginning of this decade, Schnitzbauer et al. performed right portal vein ligation and in-situ splitting and then later a second hepatic

resection. When they examined the result retrospectively, the technique showed a remarkable hypertrophic effect (74%, range: 21-192%) occurring in a median of only nine days. The hospital mortality was, however, high, as 3 of 25 patients died (12%), and 68% of the patients experienced some form of complication, with 44% experiencing severe complications⁷⁶. This approach, associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), has since evolved. The difference between ALPPS and TSH is a liver parenchyma partition in ALPPS, which is thought to have a potentially faster liver regeneration. In a recent meta-analysis, the ALPPS showed faster liver regeneration, but more complications and perioperative mortality. The postoperative functional liver volume, overall survival, and disease-free survival showed no significant difference between the methods⁷⁸. A recent multicentric randomized controlled trial found an increased resectability rate for ALPPS without a significantly increased hospital mortality (8.3% vs. 6.1%) or morbidity compared to TSH. Unfortunately, no long-term outcome is available from the study⁷⁹.

Different strategies for synchronous CRLM (sCRLM)

Three different strategies are usually available for a patient diagnosed with both colorectal cancer and liver metastases simultaneously (sCRLM).

The most traditional treatment for patients with sCRLM is the classical strategy. There the patient undergoes excision of the primary colorectal tumor followed by chemotherapy, and then if technically possible, excision of the secondary tumor or tumors later. The rationale to choose the classical strategy has been to stop a metastatic development in the primary tumor and eliminate complications from the primary tumor, e.g., tumor perforations, gastrointestinal bleeding, or bowel obstruction.

The second strategy has been to resect both the primary and metastatic tumors together, called the simultaneous strategy. This strategy is often used when a patient has a technically straightforward resection of the primary and secondary tumors. The rationale with simultaneous strategy is a single operation and anesthesia with less hospital length-of-stay.

Since many liver tumors respond well to chemotherapy, an original third approach was described in 2006 by Mentha et al.⁸⁰, where preoperative chemotherapy was administered and metastasectomy performed before the

primary tumor was finally surgically removed, named the liver-first strategy. This strategy was supposed to be applied when a patient presented with a "bad" metastatic tumor liver disease, high complication risk following the colorectal surgery, as well as to observe the chemotherapy response, or by using the refractory time after rectal cancer radio-chemotherapy⁸⁰. Mentha et al. presented a total of twenty patients who were given neoadjuvant chemotherapy with only sixteen (80%) that could follow through with the planned procedures, i.e., liver and colorectal. For the resected patients, the 5-year overall survival was 61%, equivalent to the classical strategy, but the median follow-up was only 25 months⁸⁰.




Figure 7. The image shows a predictive interval plot for the three surgical strategies, from a meta-analysis by Kelly et al⁸¹. Confidence interval (CI) as black lines and predictive intervals (PrI) as red lines. With permission from the publisher, John Wiley and Sons.

During the last decade, many retrospective studies have published comparisons between the liver-first, classical, and simultaneous strategy. To date, no randomized or controlled trial has been conducted to compare liver resection vs. no resection or between the different strategies. A meta-analysis by Kelly et al.⁸¹ compared classical, simultaneous, and liver-first strategies and found no significant survival difference. They found a total of 18 studies with 3065 patients, where 67.7% had undergone a classical strategy, 3.7% had undergone a liver-first strategy, and 28.6% had undergone a simultaneous strategy. They

found a 5-year mean odds ratio (OR) survival of 0.81 (95% CI 0.53–1.26) for a liver-first vs. a classical strategy, a mean OR survival of 0.80 (95% CI 0.52–1.24) for liver-first vs. simultaneous strategy and finally a mean OR survival of 1.02 (95% CI 0.8–1.28) for simultaneous vs. classical strategy, seen in figure 7. No difference in complications or 30-day mortality was found between the three groups⁸¹. It appears that the simultaneous strategy offers a shorter length-of-stay and less overall health costs but equal overall survival and postoperative complications^{36,81}.

To summarize, no survival difference has been demonstrated between the different strategies, although no randomized trials exist on the subject. Prior to this thesis, no national registry research was available for the comparison between the three different strategies, which was one of the aims of the study. The indications for different strategies are still evolving, and most previous studies evaluating the liver-first strategy only include liver-resected patients. Another aim of this thesis was to investigate patients intended to undergo the liver-first or the classical strategy.

Repeated resections

About 60-91% of resected CRLM patients will be diagnosed with cancer recurrence within five years, with 20 – 30% having the liver as the only site of recurrence^{50,82,83}. A repeated or even third liver resection is increasingly performed with an acceptable recurrence rate⁸³. In a systemic review from Simmonds et al., a median of 9% (range: 3.6-17%) of patients with recurrent liver metastases had repeated liver resections⁸². Wurster et al.⁸⁴ examined eight observational clinical studies with 450 patients and compared to 2669 patients that underwent single liver resections. They found that morbidity, mortality, and overall survival were comparable to one surgical resection with a survival hazard ratio (HR) of 1.00 (CI: 0.63-1.60, p=0.99)⁸⁴. Volumetric liver regeneration after repeated liver resection is poorly researched. Tanaka et al. examined 21 patients that had undergone repeated resection and found that a ratio of postoperative liver volume to preoperative liver volume was 92.0±11.7% (mean ±SD)⁷³. One of our study aims was to examine liver volume and patient outcome after repeated resection.

Registry studies

Sweden has a long history of using official population registries with unique personal identification numbers used by various governmental agencies⁸⁵. Clinical registries have been around in Sweden since 1975, and unique registries have collected information on varied diagnoses and treatments, where researchers can study outcomes for different patient groups and treatments⁸⁶. In order to examine colorectal cancers, the Swedish Rectal Cancer Registry (SRCR) was launched in 1995, and the Swedish Colon Cancer Registry (SCCR) was launched in 2007, together grouped as the Swedish Colorectal Cancer Registry (SCRCR). The SCRCR includes all clinically diagnosed patients with invasive colorectal cancers. The SCRCR has a coverage of over 99% of all patients registered⁸⁷. The National Quality Registry for Liver, Bile Duct and Gallbladder Cancer (SweLiv) was launched in 2009 and includes all patients who develop primary malignancy in the liver, gallbladder or bile ducts, as well as patients that undergo surgical or ablative treatment of secondary malignancy to the liver. SweLiv accounts for 87-97% of patients in Sweden with the above diagnoses^{88,89}.

Registry-design studies or registry-based studies (RBS) are a particular type of research with data often recorded prospectively but sometimes retrospectively. RBSs are observational research studies, from where we can access descriptive data, e.g., epidemiological data, safety data, or compare different groups of cohorts or treatments. RBSs can have different designs, such as cohort, case series, case-control, and case-cohort design. We usually consider interventional studies, such as randomized controlled trials, as having the most robust evidence grade for comparing treatment effect, but in RBSs, the cohorts are chosen beforehand. That can make comparison complicated, especially if the selection process is not transparent. Many different biases and dilemmas accompany RBSs as well, such as loss of follow-up, internal and external validations, information biases, selection biases, referral biases, confounding by indication, lead time biases, data not missing at random, and immortal time biases. However, RBSs can show us how a treatment works in "real life" with "real" clinical inclusion and exclusion criteria for an authentic population. RBSs can be especially useful where we cannot ethically intervene or randomize subjects because we are confident that the treatment or observation is inferior, superior, or harmful. Enrollment in an experimental study could, therefore, be difficult, questionable, dangerous, or perhaps unethical⁹⁰.

Different methods are increasingly used to overcome some of the difficulties of RBSs. The study subjects are evaluated according to known variables and adjusted for measurable or even unmeasurable confounders. In order to achieve this, different multivariate analyses have been applied, such as linear regression, logistic regression, Cox proportional hazard analysis, instrumental variable (IV) analysis stratification, matching, and propensity score matching⁹¹. Propensity score matching has been increasingly popular, as it gives a score of predicted probability to a control or treatment group in order to match the two groups, whereas Cox proportional analysis includes censored data and adjusts for covariates. The more complex statistical methods such as IV analysis or propensity score matching are not necessarily superior to more straightforward methods such as logistic regression and Cox proportional hazard analysis that can sometimes be more powerful when detecting differences for treatment effect^{91,92}.

Selection

Survival for patients diagnosed with metastatic colorectal cancer has steadily increased during the last decades^{20,24,25}. The reason for the increase is likely multifactorial with better awareness, diagnostic techniques, screening, hospital care, surgical techniques, and chemotherapies. In Sweden, age-adjusted mortality has declined for colon cancer but has been relatively constant for rectal cancer during the last decades^{20,22,23}. Many believed and still believe that surgical excision of all visible tumors, both the primary and metastases, is a curable treatment, although this has never been proven with controlled trials or biological models. Some have argued that more aggressive chemotherapy and metastatic surgery could explain the survival increase, but no empirical research is available to support such statements^{1,31}.

How much variation is there in resection selection? Only about 2.0% of all patients in Sweden that are diagnosed with colorectal cancer and 17.8% diagnosed with sCRLM only liver metastatic disease will undergo one or more surgical liver procedures, with considerable variation between liver centers (11.5 - 22.7%)²⁹. In England, about 2.7% of all patients that underwent colorectal surgery also had liver resections with wide variation between hospitals (0.7 - 6.8%). Older patients, with more co-morbidities, or worse socioeconomic statuses are less likely to be offered liver resection⁴⁸. The reported survival difference is great, and significant heterogeneity is between

published studies, which may account for the great variation in selection and referral to individual surgical centers⁵⁰.

How are patients selected for liver procedure, how is resectability decided, and how many patients will progress or die during the time from decision to surgery, e.g., immortal time bias? What are the intention-to-treat criteria? Are we selecting patients for metastasectomy with desirable biology that would have the same survival without any liver resection⁹³? Do the liver resected patients have similar cancer biology as patients with stage III colorectal disease⁴⁸? How many will complete the planned procedure? How do we explain the biological effect of liver surgery, and is it compatible with the most current cancer paradigm?

The role of randomization is to prevent both known and, most importantly, unknown biases. With randomization, we produce similar groups and minimize treatment assignment bias as the source for the difference in the end outcome. When done blinded (patient, examiner, and the analyzer) and with strict adherence to a rigid protocol, the randomization can, in theory, almost guarantee an unbiased estimate of the treatment effect.

Is randomization important? In the 1990s, an established treatment for breast cancer was high-dose chemotherapy (HDC) followed by haematopoietic stem-cell transplantation (HSCT), with a 3-year event-free survival of 72% compared to 5% survival without the treatment¹¹. Because of cost and toxicity, randomized controlled trials were ultimately conducted and showed no survival difference where the treatment was shortly thereafter discredited and is now no longer in use^{11,94}. As there are no randomized comparative trials or even prospective analyses of the whole group with CRLM, can we conclude for certain if CRLM resections are better than best supportive care? Can we conclude which strategy is best? Could these studies be ethically conducted?

Almost all studies that are published include only resected patients, and no studies are available that examine patients prospectively with all patients with CRLM analyzed with an intention-to-treat design. To explore the selection process, different strategy outcomes, and liver regeneration for patients, with CRLM in Sweden, this thesis was conducted.

Aims and objectives

The overall aim of this thesis was to investigate different strategies and outcomes for patients resected for liver metastases from colorectal cancer. An additional aim was to investigate volumetric liver regeneration and survival data after a repeated hepatic procedure.

In order to achieve these aims, this thesis includes four clinical studies. Each study has the following more specific objectives:

- i. Paper I: To understand why patients scheduled for the liver-first strategy do not complete both liver and primary resections.
- ii. Paper II: To investigate and compare outcomes for the liver-first and the classical strategy for patients presenting with synchronous CRLM (sCRLM).
- iii. Paper III: To investigate and compare outcomes for the simultaneous and the classical strategy for patients presenting with sCRLM, focusing on patients undergoing major liver resections.
- iv. Paper IV: To retrospectively investigate volumetric liver regeneration and survival data after a repeated hepatic procedure (resection or ablation) for recurrent CRLM.

Materials and methods

The basis of this thesis is on three different study populations of patients with CRLM.

Paper I

We analyzed the medical records of all patients with colorectal liver metastases between 2011 and August 2015 referred to a multidisciplinary team conference (MDT) at Skåne University Hospital. We further analyzed patients with synchronous liver metastases, biopsy-proven colorectal adenocarcinoma, technically resectable CRLM, and technically resectable extrahepatic metastases, when present. This group made up the patient cohort. All patients that underwent colorectal resection first, prior to or after MDT referral, were analyzed as classical strategy, and patients that underwent liver resection first were analyzed as a liver first strategy. Patients with unresected and low-symptomatic primary colorectal and unresected liver tumors were investigated with an intention-to-treat analysis after the MDT decision.

Paper II and III

We identified patients from the Swedish Colorectal Cancer registry (SCRCR) diagnosed with colorectal adenocarcinoma, and patients from the Swedish National Quality Registry for liver and biliary cancer (SweLiv) having an intervention for metastases in the liver, registered in the period between January 2008 and January 2015. We made an interconnection between the two databases using unique pseudonymous personal identification numbers. From the databases, patients with metastatic colorectal cancer to the liver after initial staging and before any resection were identified and defined as having synchronous liver metastases (sCRLM). We excluded patients that had undergone an acute colorectal resection. The subset of patients that had undergone colorectal resections within six months from the colorectal cancer

diagnosis and undergone both colorectal and liver resection within 12 months from colorectal diagnosis constituted our cohort. In paper II, we made a comparison between patients operated with the liver-first and the classical strategy. In paper III, we made a comparison between patients that had undergone simultaneous and classical strategy with particular focus on patients that had undergone a major liver resection, defined as resection of three or more Couinaud's liver segments. In paper III, a complication was identified if appearing in either or both the colorectal registry (SCRCR) and the liver registry (SweLiv). In paper II and III, a tumor burden score (TBS)⁵² in the liver was calculated as $TBS^2 = d^2 + n^2$, where d = largest liver tumor diameter (cm) and n = number of liver lesions. In paper III, an original score was invented to account for sCRLM, named total tumor burden score (TTBS) using the hazard ratio from the univariate Cox proportional hazards analysis as a multiplier if the patient had a postoperative primary lymph node-positive disease and if the patient had a T4 primary tumor. $TTBS = \sqrt{d^2 + n^2} + 2 \times N + 4 \times T$, where d = maximum liver tumor diameter (cm), n = number of liver lesions, $N = 1$ if lymph nodes are positive for the primary tumor and $T = 1$ if the primary tumor is T4, otherwise N and T had the value zero.

Paper IV

Selection of patients

All patients with CRLM who underwent a repeated procedure, resection or ablation, for a recurrent CRLM disease at Skåne University Hospital or Karolinska University Hospital, between 2005 and 2015, were analyzed. We examined further patients with available imaging from computed tomography or magnetic resonance imaging. We stratified patients into major or minor hepatic procedures. A minor hepatic procedure was defined as a hepatic resection of less than three Couinaud's segments with or without additional radiofrequency ablation (RFA) or RFA alone. We defined a synchronous disease as liver metastases diagnosed at the radiological workup of the primary colorectal cancer.

Liver volume measurements

We measured liver volumes using CT or MRI coronary plane images. We manually traced the liver contour on all liver image slices and calculated each liver area with computer software and multiplied the area by the section thickness (usually 5 mm), the sum gave the liver volume in ml. Metastasis

volumes, as well as ablation zones, were measured and subtracted from the liver volume to give a functional liver volume. We used the most recent preoperative images available before the first and repeated procedure, as well as a postoperative image taken at least one month after the repeated procedure. We then calculated relative liver volume ratios by dividing the FLV after the first and second procedures to the original FLV. For comparison, we calculated a total estimated liver volume (TELV)⁶⁷ using the formula: $TELV = -794.41 + 1,267.28 \times \text{body surface area (BSA)}$, and BSA was calculated employing the Mosteller's formula⁹⁵.

Project design

Paper I

Paper I was a retrospective, descriptive, and comparative cohort study. We retrospectively extracted data from patient records and divided patients into groups according to the treatment strategy chosen, a classical or a liver-first strategy. We excluded patients scheduled for a simultaneous strategy. The study was an intention-to-treat analysis from the MDT decision.

Paper II and III

Papers II and III were registry-based comparative cohort studies. We identified patients at the time of entry in the Swedish Colorectal Cancer registry (SCRCR) and the National Quality Registry for liver and biliary cancer (SweLiv) from January 2008 to December 2014. The registration of data was prospective.

Paper IV

Paper IV was a retrospective, descriptive, and comparative cohort study. We identified all patients with CRLM that underwent a second liver procedure for a recurrence of CRLM at Skåne University Hospital and Karolinska University Hospital, between the years 2005 and 2015.

Statistical analysis

The variables in this thesis were typically considered non-parametric. We generally presented summary statistics as whole numbers and percentages for categorical variables, or as medians with interquartile ranges (IQRs) unless otherwise stated, for continuous variables. To compare continuous variables, we used Mann–Whitney U-test, for categorical data Fischer’s-exact-test was used, and Friedman-test when comparing three continuous variable groups. Cox proportional regression analysis was used to calculate hazard ratios (HR) with 95% confidence intervals. We used Log-rank-test to assess recurrence-free and overall survival differences. Survival and recurrence-free-survival were analyzed using Kaplan Meier analysis. Pearson correlation analysis and linear regression assessed correlation and relationship, respectively. A P-value of less than 0.05 was considered statistically significant. Statistical analysis was performed using IBM SPSS Statistics version 22 (IBM, Armonk, NY, USA), for paper I. Statistical analysis for papers II-IV was performed using R (R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>).

Ethics

All the studies presented in this thesis were carried out following the Declaration of Helsinki. The Regional Ethical Review Board in Lund approved all the papers.

Results

Main findings in paper I

We identified 176 patients with resectable sCRLM, where 67 patients had already undergone resection of the colorectal primary tumor, and 109 patients had an unresected, technically resectable colorectal cancer and CRLM at the MDT, fulfilling the inclusion criteria. Two patients with planned simultaneous resections were already excluded. The median follow-up from diagnosis was 42 (30–59) months.

Of the 109 patients, 75 were scheduled for the liver-first strategy and 34 for the classical strategy. A ratio of 26/75 patients (35%) did not complete the planned treatment in the liver-first group compared to the ratio of 10/34 patients (30%) in the classical group ($P=0.664$). A disease progression was the most common reason for failure to adhere to the treatment plan, as shown in figure 8.




Figure 8A.

This figure shows a flow chart of patients planned for a liver-first strategy.




Figure 8B.

This figure shows a flow chart of patients planned for a classical strategy.

The 67 patients that had undergone resections of the primary colorectal cancer before the MDT and the 24 patients that underwent the primary resection after the MDT constituted the classical strategy group (n=91). Characteristics of these patients and the patient that accomplished the liver-first strategy are shown in table 2.

Table 2.

Characteristics of resected patients cohort. Data presented as number (percentage) or median (interquartile range). ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen. *Not included in survival analysis.

	CLASSICAL STRATEGY	LIVER-FIRST STRATEGY	P
Number of patients	91	49	
Male gender	55 (60%)	38	0.007
Age (years)	68 (63 – 74)	65 (58 – 69)	0.033
Current smoking	16 (18%)	9	1.000
Diabetes mellitus	11 (12%)	3	0.379
ASA 3	27 (30%)	14	0.706
Body mass index (kg/m ²)	25 (23 – 27)	25 (23 – 28)	0.824
Rectal primary	29 (32%)	34	<0.001
CEA at diagnosis (mg/L)	4 (2–10)	18 (6–96)	<0.001
Pathological T stage 4	28 (31%)	11	0.329
Pathological node-positive	65 (71%)	31	0.855
Number of liver tumors	2 (1–4)	2 (2–4)	0.516
Size of largest liver tumor (mm)	20 (14 – 30)	25 (20 – 45)	0.004
Synchronous lung metastases	8 (9%)	7	0.400
Major liver resection	40 (44%)	28	0.158
90-day mortality after last resection	1*	0	1.000

Median recurrence-free survival was 19 (15–24) months for the liver-first strategy group and 25 (18–31) months for the classical strategy group (n=91), with multivariate survival HR for the liver-first group of 1.23 (95% CI: 0.75 – 2.02, P=0.406), compared to the classical group. Median survival after diagnosis for the whole classical strategy group (n=91) was 60 (48–73) months compared to 46 (31–60) months for the liver-first strategy group (n = 49), P=0.310, with univariable survival HR for the liver first 1.36 (95% CI: 0.75-2.49, P=0.312), compared to the classical group.

Main findings in paper II

A total of 707 patients with sCRLM underwent liver resection, with 84 patients only undergoing liver resection but no colorectal resection. We identified 623 patients that underwent both colorectal and liver resections within 12 months, of which 246 (39%) underwent a liver-first strategy, and 377 (61%) underwent a classical strategy. The median follow-up time was 40 (27 – 57) months.

A total of 264 of the 623 patients that underwent both colorectal and liver surgery, died during the study period. The overall 5-year survival was 54% for the classical strategy group and 49% for the liver-first strategy group (P=0.344). Time from the first to the second operation was 4.7 (2.8 – 6.1) months for the classical strategy group, and 2.0 (1.4 – 3.7) months for the liver-first strategy group (P < 0.001).

Patients in the classical strategy group were older (66 vs. 62 years, P<0.001), had more T4 primary tumors (23 vs. 14%, P=0.012) and node-positive primary tumors (70 vs. 61%, P=0.015). The liver-first group had more radio-chemotherapies (92 vs. 26%, P<0.001), major liver resections (52 vs. 41 %, P=0.008), and higher liver tumor burden score (TBS, i.e., 4.1 (2.5–6.3) vs. 3.6 (2.2–5.1), P=0.003). Characteristics are shown in table 3.

We found that 281 patients had primary rectal tumors, where 115 (41%) followed the classical strategy, and 166 (59%) were treated according to the liver-first strategy. The overall 5-year survival showed no significant difference, regardless of the surgical strategy (51% vs. 47%, P=0.474).

We found that 342 patients had primary colon cancer, of which 262 (77%) followed the classical strategy, and 80 (23%) followed the liver-first strategy. The 5-year overall survival showed no significant difference between the groups, regardless of surgical strategy (56% vs. 51%, P=0.564), with multivariate survival HR of 1.09 (95% CI 0.80-1.50, P=0.576).

Table 3.

Characteristics of resected patients cohort. Values in parentheses are percentages unless indicated otherwise; *values are median (interquartile range). ASA, American Society of Anesthesiologists; BMI, body mass index; R0, radical resection; TBS, tumor burden score.

	CLASSICAL STRATEGY	LIVER-FIRST STRATEGY	P
Number of patients	377	246	
Gender (Male)	234 (62%)	161 (65%)	0.397
Age (years)*	66 (58 – 73)	62 (54 – 69)	<0.001
ASA score 3–4	74 (20%)	57 (23%)	0.365
BMI (kg/m2)*	25 (23 – 28)	25 (23 – 27)	0.127
Primary rectal cancer	115 (31%)	166 (67%)	<0.001
Chemotherapy before the first resection	97 (26%)	220 (92%)	<0.001
Radiotherapy before bowel resection	84 (22%)	153 (62%)	<0.001
T4 primary tumor	85 (23%)	35 (14%)	0.012
Lymph node-positive primary tumor	264 (70%)	149 (61%)	0.015
R0 primary tumor resection	344 (92%)	221 (91%)	0.663
Liver TBS*	3.6 (2.2 – 5.1)	4.1 (2.5–6.3)	0.003
Major liver resection	152 (41%)	125 (52%)	0.008
R0 liver resection	262 (86%)	173 (86%)	0.896

Eighty-four patients underwent liver but no colorectal resections. Patient characteristics are shown in table 4. The only-liver-resection group had an overall 5-year survival of 14 (8 – 28) %.

Table 4.

Characteristics of resected patients cohort. Values in parentheses are percentages unless indicated otherwise; *values are median (interquartile range). ASA, American Society of Anesthesiologists; BMI, body mass index; R0, radical resection; TBS, tumor burden score.

	ONLY-LIVER-RESECTION	LIVER-FIRST STRATEGY	P
Number of patients	84	246	
Gender (Male)	65 (77%)	161 (65%)	0.043
Age (years)*	66 (58 – 72)	62 (54 – 69)	0.007
ASA score 3–4	16 (19%)	57 (23%)	0.451
T4 primary tumour (preoperative)	22 (34%)	35 (14%)	<0.001
Lymph node positive primary tumour (preoperative)	49 (72%)	161 (75%)	0.637
Primary rectal tumour	63 (75%)	166 (67%)	0.219
Chemotherapy before liver resection	71 (85%)	220 (90%)	0.165
Liver TBS*	4.9 (2.8 – 9.0)	4.1 (2.5 – 5.0)	<0.001
Major liver resection	35 (52%)	125 (52%)	1
R0 liver resection	39 (66%)	173 (86%)	0.002

Main findings in paper III

From SCRCR, we identified 39,016 patients diagnosed with colorectal cancer, of which 6,105 (16%) patients had liver metastases (sCRLM) at the time of diagnosis. Of the CRLM patients, a total of 1,571 (26%) underwent elective surgery of the primary colorectal tumor, and 783 patients (50%) underwent both colorectal and liver resections, constituting two percent of the initially identified patient group (n=39,016) and 13% of the patients with sCRLM (n=6,105), as seen in Figure 9. We found 377 patients that had followed the classical strategy and 160 that followed the simultaneous strategy, resulting in a total of 537 patients. The follow-up time had a median of 41 (27 – 58) months.




Figure 9.
The study cohort population from SCRCR and SweLiv.

Patients in the simultaneous strategy group had fewer rectal primary tumors (22% vs. 31%, $p=0.046$), fewer major liver resections (16% vs. 41%, $p<0.001$), fewer neoadjuvant chemotherapies (64 vs 73 %, $p=0.029$), less total bleeding

(600 vs 850 ml, <0.001), as well as a shorter total length-of-stay (11 vs. 15 days, p<0.001). The simultaneous strategy group had, however, a higher total complication rate from either the colorectal or liver procedure that demanded treatment (52% vs. 36%, p<0.001). Patient characteristics are shown in Table 5. We found a no significant overall survival difference between the groups (P=0.110), with a 5-year survival of 54% in the classical strategy group and 46% in the simultaneous strategy group, with a median survival of 49 and 58 months and a multivariate survival HR of 0.83 (95% CI: 0.6-1.14) for the simultaneous group compared to the classical group, P=0.243.

A total of 25 patients had a major liver resection in the simultaneous group and 155 in the classical strategy group, with no significant difference in 5-year overall survival (P=0.198).

Table 5.

Characteristics of the resected patient cohort. Percentages are in parentheses unless otherwise indicated: * median (interquartile range). ASA, American Society of Anesthesiologists. BMI, Body mass index. R0, Radical resection.

	CLASSICAL STRATEGY	SIMULTANEOUS STRATEGY	P
Patients	377	160	
Male	234 (62%)	90 (56%)	0.211
Age (years)*	66(58-73)	65(58-72)	0.396
ASA (3-4)	74 (20%)	32 (20%)	0.906
BMI (kg/m ²)	25.4(23.1-27.5)	24.9(22.5-27.8)	0.434
Preoperative radiotherapy	84 (22%)	29 (18%)	0.300
Neoadjuvant chemotherapy	274 (73%)	101 (64%)	0.029
Localization (rectum)	115 (31%)	35 (22%)	0.046
T4 primary	85 (23%)	41 (26%)	0.435
Lymphatic node-positive, primary tumors	264 (70%)	105 (66%)	0.411
Number of liver tumors*	2(1-4)	2(1-4)	1
Liver tumor size (mm)*	20(14-35)	20(12-30)	0.202
Tumor burden score*	3.6(2.2-4.2)	3.2(2.1-4.5)	0.500
Portal vein embolization	15 (4%)	0 (0)	0.008
Major liver surgery	152 (41%)	25 (16%)	<0.001
R0 liver resection	350 (93%)	145 (91%)	0.370
Total loss of blood (ml)	850(474-1456)	600(250-950)	<0.001
Total complications, demanding treatment	136 (36%)	84 (52%)	<0.001
Total length-of-stay (days)*	15(12-20)	11(8-15)	<0.001

We identified 135 patients that underwent a minor liver resection in the simultaneous group and 222 in the classical group. The simultaneous minor group had: fewer rectal primary tumors (5 vs 33%, p < 0.001), less total bleeding (600 (300 - 900) vs. 700 (350-1250) ml, p=0.003) and shorter total

length-of-stay (11 (7 - 15) vs 16 (14 - 20) days, $p < 0.001$) compared to classical minor group. No other difference was found to be significant between the groups. The overall 5-year survival showed no significant difference ($P=0.131$).

When comparing the group with elective colorectal and no liver surgery (primary only, $n=788$) to the simultaneous group, we found that the primary only group was older (72 (64-79) years, $P<0.001$), had more T4 primary tumors (291 (37%), $P=0.010$), more node-positive primaries (630 (82%), $p < 0.001$), and a higher proportion of patients with ASA 3-4 (228 (29%), $P=0.027$). The primary only group had an 11% 5-year overall survival and a median survival of 15 months.

A new score applicable to patients with sCRLM was calculated (TTBS). After stratification of the TTBS into three subgroups - $TTBS < 5$, $TTBS \geq 5$ and < 10 and $TTBS \geq 10$, - we found a 3-year overall survival 80.7%, 59.6% and 21.7% respectively, $p < 0.001$. The TTBS had a similar area under the curve (AUC) as the previous tumor burden score, 0.688 vs. 0.628, respectively, $p=0.100$.

Main findings in paper IV

Ninety-nine patients with recurrent CRLM underwent a repeated (second) procedure. Images before the first and second procedures and after the second procedure were available for 82 patients, which constituted our study cohort. Median follow-up was 53 (40-71) months from the first procedure.

The initial functional-liver-volume (FLV) was 1584 (1313–1927) ml, compared to 1438 (1204–1896) ml after the initial procedure, and 1470 (1172–1699) ml after the repeated procedure ($P < 0.001$).

Liver volumes ratios after initial resections and repeated resections divided by the initial FLVs showed no significant difference, $P=0.532$, shown in figure 10. After the first procedure, nine patients had a FLV of less than 75% of the original FLV, and ten patients had a FLV of less than 75% of the initial FLV after the second procedure.




Figure 10.

Liver volume ratios after the first and second procedures divided by the original function liver volume (FLV).

Patients that underwent only minor procedures had no significant reduction in liver volume ($P=0.621$ and $P=0.792$, respectively). Patients that underwent one major and one minor procedure had significantly smaller liver volume after the repeated procedure compared to patients only undergoing minor procedures, 87 (79–101) % vs. 98 (86–108) % respectively, $P=0.013$.

We discovered no significant difference in liver volume for patients receiving chemotherapy ($n=74$) compared to those not receiving chemotherapy ($n=8$), 100 (95–108) % vs. 91 (80–103) %, $P=0.200$.

After the first procedure, we found an overall 5-year survival of 60 (47–70) % and 37 (26–54) % after the repeated procedure. We found no significant difference in complication rate (Clavien-Dindo classification ≥ 3) between the first procedure (13 patients (16%)) and the second procedure (15 patients (18%)), $P=0.846$.

A linear correlation between total estimated liver volume (TELV) and measured FLV before the initial, before the repeated, and after the repeated procedures showed a correlation of $r=0.57$, $r=0.68$, and $r=0.55$, respectively ($P<0.001$).

General discussion

The liver-first strategy, as introduced by Mentha et al.⁸⁰, includes preoperative chemotherapy, resection of the colorectal liver metastases followed by resection of the primary colorectal cancer at a later stage. One rationale for this strategy is the risk of liver metastases progression beyond resectability during the time it takes to go through the primary resection, especially in case of advanced liver disease or major complications following colorectal surgery. Another theoretical advantage of the liver-first strategy is the time-window interval between the preoperative chemoradiotherapy and resection for the advanced rectal cancers where the surgeon can resect the liver metastases. As stated in the introduction chapter, patient selection is uncertain, and most studies only analyze already resected patients. Most patients will experience a disease progression after metastasectomy, with repeated resections having an acceptable recurrence rate and survival compared to after the first resection. It is uncertain how the liver volume regenerates after a repeated resection for CRLM.

Paper I

STRENGTHS	LIMITATIONS	KEY ASSUMPTIONS
One large Swedish liver center. Descriptive and comparative analysis of the treatment process for patients with sCRLM after the MDT selection.	Retrospective. Non-randomized. Groups are not equal. Troublesome to generalize because of the variation between hospitals. A limited number of patients. Patient selection to the MDT unknown.	About one in three will not complete a planned treatment, most often because of disease progression.

There was no significant difference between groups concerning T4 stage or node-positive primaries, reflecting that the extent of liver disease is perhaps the most crucial factor when selecting patients for each strategy. No significant survival difference was found between the liver-first strategy or the classical

strategy, which is comparable to other studies⁸¹, particularly noting the more severe liver tumor burden in patients chosen to the liver-first strategy, as previously shown⁹⁶. We found that 35% of patients selected for the liver-first strategy could not accomplish the planned treatment strategy, which is slightly higher than previously published (20 - 32%)^{80,97,98}. It may seem excessive, but it was similar and not significantly higher than the classical strategy planned group, with a ratio of 10/34 (29%). The reason for not completing was tumor progression, highlighting the importance of including patients that are assigned to a treatment plan but will not complete it when evaluating the effectiveness of different strategies.

Paper II

STRENGTHS	LIMITATIONS	KEY ASSUMPTIONS
Register-based study for the whole of Sweden. The study shows the current practice with real patient outcomes and clinical inclusions.	Non-randomized. No intention to treat analysis. Selection bias. Variation between hospitals. Disease-free survival was difficult to deduce.	The liver-first strategy group had more rectal primary tumors, advanced liver disease, and fewer node-positive primaries compared to the classical group Survival did not differ significantly.

Patients chosen to the liver-first strategy were significantly younger, had fewer lymph node-positive tumors, and underwent more major-liver resections compared to patients allocated to the classical strategy. Also, the liver-first group had more primary rectal cancers and had a higher ratio of preoperative radio-chemotherapy, probably reflecting the opportunity to perform liver surgery during the waiting time after the treatment for rectal cancer. No significant difference was noted in five-year overall survival between the groups (54% vs. 49%, $P=0.344$), as well as after adjusting for confounders.

The liver TBS, as previously described by Sasaki et al., has shown a discriminatory prognostic power and may be used for calculating survival differences. The concept is similar to the 'metro ticket' prognostic system introduced for liver transplantation for hepatocellular carcinoma^{52,99}. The liver-first group had a more advanced liver TBS, most probably illustrating that the liver-first strategy is increasingly applied when patients present with advanced liver metastases and a low-symptomatic primary tumor. The motivation presumably to first remove the tumors believed to be more threatening to patient health.

Eighty-four patients underwent liver resection but no colorectal resection. The reasons are unknown from the patient registers, but in the paper I, we had up to 35% of patients not completing the intended treatment. The patients who only underwent liver resection were older and had more advanced primary tumors, more advanced liver tumors, and fewer radical liver resection margins compared to patients completing the two resections in the liver-first group.

Paper III

STRENGTHS	LIMITATIONS	KEY ASSUMPTIONS
Register-based study for the whole of Sweden. Shows current practice and real patient outcomes with clinical inclusions.	Non-randomized. No intention to treat analysis. Selection bias. Variation between hospitals. Disease-free survival was difficult to deduce. Complications were difficult to sub-analyze.	Patients selected for simultaneous liver and primary resection had a shorter total length-of-stay, similar overall survival but higher complication rate in comparison to patients selected to a classical strategy.

We found that the simultaneous strategy group had a shorter total length-of-stay, fewer rectal primaries, more complications that demanded treatments, fewer major liver resections, and less total bleeding compared to the classical strategy group. It was not possible to classify the morbidity, e.g., with the Clavien-Dindo classification. This can make a comparison with previous studies difficult. We did not find any difference regarding gender, age, ASA score, BMI, radiotherapy, T4 primary, lymph node-positive primary, number of liver metastases, liver tumor size, total tumor burden in the liver, or R0 liver resections between the study groups. Patients are perhaps selected based on the extent of the planned liver and colorectal surgery. Despite the higher complication rate in the simultaneous strategy group, the total length-of-stay was shorter, perhaps denoting less clinically significant complications. No significant difference in overall survival was found between the groups, both before and after adjustment, as reported in previous studies^{36,81}.

The novel TTBS score, subdivided into three groups, showed a significant overall survival difference between the groups but with a similar area under the curve (AUC) to the previous tumor burden score (p=0.100). The most unfavorable group had a very poor overall survival, but no external validation has been made.

When comparing the groups of patients that underwent major-liver resections (simultaneous vs. classical strategy), we found no significant difference in 5-year overall survival, but the simultaneous major-liver resection group was small (n=25).

Paper IV

STRENGTHS	LIMITATIONS	KEY ASSUMPTIONS
<p>A retrospective cohort study from two large liver centers. A reasonably large number of patients.</p>	<p>Non-randomized. No intention to treat analysis. Selection bias. Immortal time bias. Variation between hospitals. Intervariation between observers. Liver resection not measured peri- or postoperatively. No information was available about histological parenchymal damage.</p>	<p>Small changes in FLV were found after two liver procedures but with a noticeable inter-individual variation.</p>

The liver has a remarkable regenerative ability. After repeated procedures, it is essential to estimate liver regeneration when scheduling a second or even a third liver procedure.

The liver volume decreased minimally and nearly reached the preoperative volume, for most patients, after two liver procedures. This being similar to results from one previously published study on the subject, which included 21 patients⁷³. We found a noticeable unknown inter-individual variation, with ten patients who had an FLV of less than 75% of the initial FLV after the second procedure. Minor procedures did not change the liver volume significantly, but we found a significant reduction in FLV after major-resections.

We found no significant difference in liver regeneration for patients that received chemotherapy vs. those that received none, but that group was small (n=8).

Total estimated liver volume (TELV) and measured total liver volumes had r^2 values between 0.30–0.46, indicating that the formula explains only 30–46% of the variability in the measured volume. More studies are needed to address this issue.

The overall 5-year survival was 37 (26–54) % after the repeated procedure, in line with previous publications. A considerable variation in survival is found in the published literature, with 5-year overall survival ranging between 3.5 – 55% after repeated resections^{100,101}.

Conclusions

- About 35% of patients with sCRLM do not complete the intended treatment of liver and colorectal resections, regardless of the treatment strategy.
- The liver-first strategy is currently the dominant strategy for sCRLM in patients with rectal cancer in Sweden. We found no significant difference in overall survival between the liver-first and the classical strategies.
- Simultaneous resection for the primary colorectal cancer and liver metastases appears to have more complications but with no significant difference in overall survival compared to the classical strategy.
- Small changes in FLV were found after two liver procedures but with a noticeable inter-individual variation. We found an acceptable survival for patients chosen for a repeated hepatic procedure for recurrent CRLM.

Future challenges

Colorectal cancer is a common disease that affects approximately 6,500 patients each year in Sweden, and about 2,000 patients will be diagnosed with CRLM each year. Even though we now have better screening, oncological- and surgical treatments, age-adjusted mortality has decreased for colon cancer but has been relatively stable for rectal cancer^{20,22,23}. When looking at causality, we often refer to the father of epidemiology and medical statistics, Sir Austin Bradford Hill. In his 1965 publication, nine critical criteria to establish a causal relationship were listed¹⁰²:

- strength of association, i.e., a more significant association means a stronger causal relationship.
- consistency, i.e., consistency between multiple studies.
- specificity, i.e., a "single" factor that explains the causation.
- temporality, i.e., an exposure or treatment, comes before an outcome.
- biological gradient, i.e., the dose-response relationship, is found.
- plausibility, i.e., different models can explain the causation.
- coherence, i.e., can be explained by current knowledge or paradigm.
- experiment, i.e., experimental studies that can explain the observational studies.
- analogy, i.e., is there another similar causation.

A few more causality assumptions are nowadays essential in order to assess causality, e.g., the ignorability assumption where outcomes are independent of the treatment, the stable unit treatment value assumption (SUTVA) where outcomes of one is unaffected by assignment of other, and the positivity assumption, where an individual has a positive probability of receiving treatment¹⁰³.

Can this thesis fulfill the above causality assumptions and Bradford Hills criteria? Is there enough evidence to conclude which strategy is best for sCRLM? Is there enough evidence to conclude how we select patients with a real prospective intention to treat analyses? Is the treatment independent of the outcome? Do similar patients get the same chance of treatment? Are the studies consistent and plausible enough? Is the biological paradigm of metastatic cancer coherent to surgical and ablative treatments of CRLM? Do we need experimental studies such as controlled trials or randomized controlled trials on the subject?

In order to continue our work and answer the questions above, further studies are needed.

- A prospective intention to treat analysis for all patients diagnosed with colorectal cancer disease is needed. There we would hopefully understand the selection process better.
- A multicenter randomized controlled trial for patients with technically resectable sCRLM is needed. There we could compare the classical, liver-first, and simultaneous strategy. We could even have the fourth strategy, where patients would only receive the best supportive therapy. In order to organize the trial, vast resources would be needed, with cooperation from many surgical centers. The ethical aspect of having a patient group only receiving the best supportive treatment would need extensive ethical consideration. By conducting a controlled trial, we could hopefully limit confounders and answer which strategy is best, and if liver resection is superior to supportive therapy.
- A prospective evaluation of liver regeneration after both single and repeated liver resections for CRLM is needed. There, both the liver function and exact liver resection volume could be calculated.

Populärvetenskaplig sammanfattning på svenska

Introduktion

Cancer är en mycket vanlig sjukdom och en av fyra kommer att drabbas under livets gång. Under senare tid har man kunnat behandla spridd cancer med bra överlevnadsmöjligheter. Ändtarms- och tjocktarmscancer är den tredje vanligaste canceren i Sverige och ca 6 500 patienter diagnostiseras varje år. Ungefär var femte patient har redan spridning till levern vid upptäckt av cancer. Vi tror att bästa tillgängliga behandlingen är att operera bort tumörerna, när det är möjligt.

Hur vet vi vilken behandling är bäst för patienter med samtidig tarm- och levercancer? Tänk dig att man står framför tre olika dörrar och måste välja rätt. Bakom första dörren har vi den mest kända tekniken som kallas tarmen-först, där opererar vi bort tarmtumören och sedan levermetastaserna med en annan operation senare. Bakom nästa dörr har vi levern-först-tekniken, där levermetastaserna opereras innan tumören i tarmen. Slutligen finns den sista dörren där alla tumörer i både levern och tarmen tas bort vid samma operationstillfälle, den simultana-tekniken.

Hur många patienter som man planerar för både lever- och tarmkirurgi kommer att genomgå operation av både levern och tarmtumören? Spelar det roll på vilket sätt man väljer att operera cancer som har spritt sig till levern och slutligen, hur växer levern när man har genomgått två operationer i levern?

Artikel 1

I det första arbetet undersökte vi hur många av patienterna som vi väljer till lever- och tarmkirurgi genomgår den planerade behandlingen i verkligheten. Vi undersökte alla patienter som hade tarmcancer och metastaser till levern och skickades med remiss till Skånes Universitetssjukhus mellan 2011 och 2015. Vi identifierade 109 patienter som planerades till operation, 75 patienter planerades till levern-först och 34 till tarmen-först. Tjugosex patienter (35%)

lyckades inte fullföra behandlingen i levern-först gruppen jämfört med 10 (29%) i tarmen-först gruppen (ingen signifikant skillnad). Orsaken till misslyckande var oftast sjukdomens progression. Medianöverlevnaden var 46 (31–60) månader i gruppen som opererades med lever-först-tekniken.

Artikel 2

Det andra arbetet handlade om skillnaden mellan tarmen-först-tekniken och levern-först-tekniken. Vi använde två nationella register i Sverige mellan åren 2008 och 2015 och där kunde vi kartlägga och jämföra om det fanns någon skillnad vad gäller överlevnad och behandlingsresultat. Vi identifierade 623 patienter, varav 246 hade genomgått levern-först-tekniken och 377 tarmen-först-tekniken. Patienter i tarmen-först gruppen hade oftare signifikant sämre tarmtumörer (23% vs. 14%) och lymfkörtel positiva tarmtumörer (70 vs. 61%). Vi hittade ingen överlevnadsskillnad efter 5 år. En majoritet (59%) av patienter med rektalcancer behandlades med levern-först tekniken.

Artikel 3

Det tredje arbete handlade om skillnaden mellan tarmen-först-tekniken och den samtidiga-tekniken. Vi använde igen två nationella register i Sverige mellan åren 2008 och 2015 och jämförde och kartlagde skillnaden mellan teknikerna. Vi identifierade 537 patienter, varav 160 genomgick den samtidiga-tekniken. Patienter som hanterades med den samtidiga-tekniken hade färre primära tumörer i ändtarmen (22 vs. 31%), genomgick mer sällan stor leverkirurgi (16 vs. 41%), hade signifikant kortare total sjukhusvistelse (11 vs. 15 dagar) men fler behandlingskrävande komplikationer (52 vs. 36%). Ingen signifikant skillnad påträffades i femårs överlevnad. Totalt 25 patienter genomgick en stor leverresektion i den samtidiga gruppen. Där hittade vi ingen signifikant skillnad i femårsöverlevnad.

Artikel 4

Det fjärde arbetet handlade om att radiologiskt mäta leverns tillväxt och undersöka överlevnadsdata efter en upprepad leverprocedur för återkommande metastas i levern. Den initiala levervolymen (FLV) var 1584 (1313–1927) ml. FLV var 1438 (1204–1896) ml efter den första proceduren och 1470 (1172–1699) ml efter den andra proceduren. Signifikant skillnad fanns mellan mätningarna. Efter den andra proceduren hade tio patienter (12%) en återstående levervolym på mindre än 75% av den ursprungliga levervolymen. Den femåriga överlevnaden var 37 (26–54) % efter den andra proceduren.

Slutsatser

Upp till 35% av patienterna med tjock- och ändtarmscancer och synkrona levermetastaser slutför inte den planerade behandlingen av lever- och tarmresektioner, oavsett behandlingsstrategi.

Levern-först-tekniken är för närvarande den dominerande strategin för patienter med ändtarmscancer och levermetastaser i Sverige. Ingen signifikant skillnad i överlevnad observerades mellan levern-först och tarmen-först-tekniken.

Samtidig resektion av tarmcancer och levermetastaser verkar ha fler komplikationer men utan någon signifikant skillnad i överlevnad jämfört med tarmen-först-tekniken.

Icke-signifikanta skillnader påvisades i leverns tillväxt efter två leverprocedurer men betydande variationer för ett fåtal patienter. Patienter utvalda för en upprepad leverprocedur för återkommande CRLM hade en acceptabel överlevnad.

Vísindaleg samantekt á íslensku

Inngangur

Krabbamein er algengur sjúkdómur. Fyrir ekki svo löngu síðan var útbreitt krabbamein ólæknandi en í seinni tíð hafa lífslíkur aukist. Ristil- og endaparmskrabbamein (þarmakrabbamein) er þriðja algengasta krabbameinið í Svíðþjóð og um 6.500 sjúklingar greinast á ári hverju. Um það bil einn af hverjum fimm sjúklingum hefur, þegar við greiningu, meinvörp í lifur. Best er að fjarlægja frumæxlið og meinvörpin, ef það er mögulegt á annað borð.

Þrjár mismunandi aðferðir eru í boði fyrir sjúklinga sem greinast samtímis með krabbamein í þörmum og lifur. Fyrsta aðferðin hefur þekkt hvað lengst og kallast klassíska aðferðin (KA), þar sem æxlið í þarminum er fjarlægt fyrst og meinvörp í lifur eru fjarlægð síðar með annarri aðgerð. Næsta aðferðin er lifrin-fyrst aðferðin (LFA), en þar meðhöndlast lifrarmeinvörpin fyrst og krabbameinið í þörmunum síðar. Að lokum kemur samhliða aðferðin (SA) þar sem allt krabbameinið, þ.e. æxlið í þörmunum og lifrarmeinvörpin, eru fjarlægð á sama tíma.

Hve margir sjúklingar gangast undir þá aðgerð sem er fyrirfram ákveðin? Skiptir máli hvaða aðferð við veljum þ.e. klassíska, lifrin-fyrst eða samhliða aðferðina? Hvernig vex lifrin eftir enduraðgerð?

Grein 1

Í fyrstu greininni könnuðum við hve margir sjúklingar gangast undir þá meðferð sem var fyrirfram ákveðin. Við skoðuðum alla sjúklinga sem voru með ristil- og endaparmskrabbamein með lifrarmeinvörp, metnir á Háskólasjúkrahúsinu á Skáni á árunum 2011 til 2015. Sjötíu-og-sex sjúklingar voru fyrirfram valdir í LFA hópinn og 34 í KA hópinn. Tuttugu-og-sex sjúklingar (35%) í LFA hópnum náðu ekki að ljúka áætlaðri meðferð samanborið við tíu (29%) í KA hópnum, með engum tölfræðilegum mun. Orsök fyrir því að ekki tókst að ljúka skipulagðri meðferð var versnun á krabbameinssjúkdómnum.

Grein 2

Næsta grein fjallaði um muninn á KA og LFA. Við notuðum tvö sjúklingagagnasöfn í Svíþjóð milli árána 2008 og 2015 þar sem við gátum kortlagt og borið saman hvort það var munur hvað varðar lifun og meðferðarárangur. Við bárum mat á 623 sjúklinga, þar af voru 246 í LFA hópnum og 377 voru í KA hópnum. Sjúklingar í KA hópnum höfðu oftara þarmkrabbamein (23% á móti 14%) og eitilvöxt (70% á móti 61%). Við fundum engan tölfræðilegan fimm ára mun á lífslíkum. Meirihluti (59%) sjúklinga með krabbamein í endaparmi voru meðhöndlaðir með LFA.

Grein 3

Þriðja greinin fjallaði um muninn á KA og SA. Við notuðum aftur sömu sjúklingagagnasöfn í Svíþjóð milli árána 2008 og 2015 og bárum saman og kortlögðum mismuninn á aðferðunum. Við máttum 537 sjúklinga, þar af 160 sem voru í SA hópnum. Sjúklingar í þeim hóp voru marktækt ólíklegri til að hafa frumæxli í endaparminum (22% á móti 31%), ólíklegri til að gangast undir stóra lifraraðgerð (16% á móti 41%), höfðu styttri legutíma (11 á móti 15 dögum) en fleiri fylgikvilla (52% á móti 36%). Enginn marktækur munur fannst á fimm ára lífslíkum. Alls fóru 25 sjúklingar í stóra lifrarskurðaðgerð í SA hópnum.

Grein 4

Fjórða grein okkar fólst í að mæla vöxt lifrarinnar með myndgreiningartækni og kanna lifun eftir enduraðgerð við endurkomu á lifrarmeinvörpum. Upphaflegt lifrarrúmmál (FLV) var 1584 (1313-1927) ml. FLV var 1438 (1204-1896) ml eftir fyrstu aðgerðina og 1470 (1172-1699) ml eftir seinni aðgerðina. Marktækur munur var á milli lifrarmælinganna. Eftir seinni aðgerðina höfðu tíu sjúklingar (12%) minna en 75% af upphaflegu lifrarrúmmáli. Fimm ára lífslíkur voru 37 (26-54) % eftir seinni aðgerðina.

Niðurstöður

Allt að 35% af sjúklingum með þarmkrabbamein og lifrarmeinvörp ljúka ekki fyrirhugaðri meðferð, óháð meðferðaráætlun.

Í Svíþjóð er lifur-fyrst aðferðin ráðandi hjá sjúklingum með bæði krabbamein í endaparmi og lifrarmeinvörp. Enginn tölfræðilegur munur var á lífslíkum milli lifrin-fyrst og klassísku aðferðarinnar.

Samhliða aðferðin á krabbameini í þörmum og lifur virðist hafa meiri fylgikvilla en án nokkurs marktækts munar á lífslíkum miðað við klassísku aðferðina.

Litlar breytingar á lifrarstærð fundust í kjölfar endurtekinna lifraraðgerða en töluverður breytileiki var á milli einstakra sjúklinga. Sjúklingar sem fara í enduraðgerð vegna endurkomu á lifrarmeinvörpum hafa viðunandi lífslíkur.

Errata

- In paper I, under the chapter: Discussion, paragraph 2:
 - *Table 1* is supposed to be written instead of *table 2* after,clinical node-positive primaries.....
- In paper II, table 4, the parameter Liver TBS for the Completed liver-first strategy group:
 - ...*should be 4.1 (2.5 – 5.0) instead of 2.5 (4.1 – 5.0)*....
- In paper IV under the chapter: Selection of patients:
 - resection *of three or more* Couinaud's is to be written instead of resection *of more than three* Couinaud's

Acknowledgments

My highest gratitude and appreciation to:

-my university, Lund University

-my supervisor, Christian Sturesson

-my co-supervisor, Ingvar Syk

-my co-authors

-my co-workers, especially Hanna Sternby, Stefan Santén, and Bodil Andersson

-my workplace, Skåne University Hospital

-my mother, Hrönn, and stepfather, Guðjón

-my father, Valdimar, and grandfather, Þórhallur

-my siblings, Ari, Hafdís, and Þórir

-my in-laws, Guðjón, and Guðný

-last but not least...

-my wife, Erla Þóra that has helped and assisted me
in more ways than imaginable

-my wonderful sons, Guðjón Ari and Ármann Óli!

References

1. Flanagan L, Foster JH. Hepatic resection for metastatic cancer. *American journal of surgery*. 1967;113:551–7.
2. Hajdu SI. A note from history: Landmarks in history of cancer, part 1. *Cancer*. 2011;117:1097–1102.
3. Cancer | Definition of Cancer by Merriam-Webster Available from: <https://www.merriam-webster.com/dictionary/cancer>. Accessed October 27, 2019.
4. Cancer Statistics - National Cancer Institute Available from: <https://www.cancer.gov/about-cancer/understanding/statistics>. Accessed September 24, 2019.
5. Klein CA. Cancer: The metastasis cascade. *Science*. 2008;321:1785–1787.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell*. 2011;144:646–674.
7. Anderson RL, Balasas T, Callaghan J, et al. A framework for the development of effective anti-metastatic agents. *Nature Reviews Clinical Oncology*. 2019;16:185–204.
8. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. *Nature Medicine*. 2006;12:895–904.
9. Naxerova K, Reiter JG, Brachtel E, et al. Origins of lymphatic and distant metastases in human colorectal cancer. *Science*. 2017;357:55–60.
10. Chintamani. The paradigm shifts in the management of breast cancer- have we finally arrived? *The Indian journal of surgery*. 2013;75:419–23.
11. Palma DA, Salama JK, Lo SS, et al. The oligometastatic state- separating truth from wishful thinking. *Nature Reviews Clinical Oncology*. 2014;11:549–557.

12. Hajdu SI, Darvishian F. A note from history: Landmarks in history of cancer, part 5. *Cancer*. 2013;119:1450–1466.
13. Fisher B, Anderson SJ. The breast cancer alternative hypothesis: Is there evidence to justify replacing it? *Journal of Clinical Oncology*. 2010;28:366–374.
14. Hellman S. Natural history of small breast cancers. *Journal of Clinical Oncology*. 1994;12:2229–2234.
15. Coumans FAW, Siesling S, Terstappen LWMM. Detection of cancer before distant metastasis. *BMC cancer*. 2013;13:283.
16. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. *Nature Reviews Cancer*. 2004;4:448–456.
17. Welch DR. Do we need to redefine a cancer metastasis and staging definitions? *Breast disease*. 2006;26:3–12.
18. Wind J, Tuynman JB, Tibbe AGJ, et al. Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood. *European Journal of Surgical Oncology*. 2009;35:942–950.
19. Chun YS, Passot G, Yamashita S, et al. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. *Annals of surgery*. 2019;269:917–923.
20. Ayoubi S, Redaktör S, Johansson E, et al. CANCER I SIFFROR 2018 Available from: www.socialstyrelsen.se. 2018. Accessed October 26, 2019.
21. Statistikdatabaser - Cancerstatistik - Resultat Available from: https://sdb.socialstyrelsen.se/if_can/resultat.aspx. Accessed September 4, 2019.
22. The NORDCAN project. Cancer statistics for the Nordic countries. *Version 8.2 (26.03.2019)*.
23. Tjock-och ändtarmscancer Nationellt vårdprogram Landstingens och regionernas nationella samverkansgrupp inom cancervården Available from: www.cancercentrum.se. Accessed September 4, 2019.
24. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. *Journal of Clinical Oncology*. 2009;27:3677–3683.
25. Jawed I, Wilkerson J, Prasad V, et al. Colorectal cancer survival gains

- and novel treatment regimens a systematic review and analysis. *JAMA Oncology*. 2015;1:787–795.
26. Tjock- och ändtarmscancer Available from: <https://www.cancercentrum.se/syd/cancerdiagnoser/tjocktarm-andtarm-och-anal/tjock--och-andtarm/>. Accessed September 4, 2019.
 27. Elferink MAG, de Jong KP, Klaase JM, et al. Metachronous metastases from colorectal cancer: a population-based study in North-East Netherlands. *International Journal of Colorectal Disease*. 2015;30:205–212.
 28. Riihimäki M, Hemminki A, Sundquist J, et al. Patterns of metastasis in colon and rectal cancer. *Scientific Reports*. 2016;6:29765.
 29. Noren A, Eriksson HG, Olsson LI. Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study. *Eur J Cancer*. 2016;53:105–114.
 30. Leporrier J, Maurel J, Chiche L, et al. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. *British Journal of Surgery*. 2006;93:465–474.
 31. Möller W. Leberresektion wegen krebs metastase. *Acta chir scandinav*. 1935;78:103.
 32. Strasberg SM. Nomenclature of hepatic anatomy and resections: A review of the Brisbane 2000 system. *Journal of Hepato-Biliary-Pancreatic Surgery*. 2005;12:351–355.
 33. Brown RS. Live Donors in Liver Transplantation. *Gastroenterology*. 2008;134:1802–1813.
 34. Stureson C, Nilsson J, Eriksson S, et al. Limiting factors for liver regeneration after a major hepatic resection for colorectal cancer metastases. *Hpb*. 2013;15:646–652.
 35. Simoneau E, Alanazi R, Alshenaifi J, et al. Neoadjuvant chemotherapy does not impair liver regeneration following hepatectomy or portal vein embolization for colorectal cancer liver metastases. *Journal of Surgical Oncology*. 2016;113:449–455.
 36. Gavriilidis P, Sutcliffe RP, Hodson J, et al. Simultaneous versus delayed hepatectomy for synchronous colorectal liver metastases: a systematic review and meta-analysis. *HPB*. 2018;20:11–19.
 37. Kasai M, Cipriani F, Gayet B, et al. Laparoscopic versus open major hepatectomy: a systematic review and meta-analysis of individual

- patient data. *Surgery (United States)*. 2018;163:985–995.
38. Wei MT, He YZ, Wang JR, et al. Laparoscopic versus open hepatectomy with or without synchronous colectomy for colorectal liver metastasis: A meta-analysis. *PLoS ONE*. 2014;9:e87461.
 39. Diaz-Nieto R, Fenwick S, Malik H, et al. Defining the Optimal Use of Ablation for Metastatic Colorectal Cancer to the Liver Without High-Level Evidence. *Current Treatment Options in Oncology*. 2017;18:8.
 40. Knavel EM, Brace CL. Tumor ablation: Common modalities and general practices. *Techniques in Vascular and Interventional Radiology*. 2013;16:192–200.
 41. Abdalla EK, Vauthey J-N, Ellis LM, et al. Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases. *Annals of Surgery*. 2004;239:818–827.
 42. van Amerongen MJ, Jenniskens SFM, van den Boezem PB, et al. Radiofrequency ablation compared to surgical resection for curative treatment of patients with colorectal liver metastases – a meta-analysis. *HPB*. 2017;19:749–756.
 43. Weng M, Zhang Y, Zhou D, et al. Radiofrequency Ablation versus Resection for Colorectal Cancer Liver Metastases: A Meta-Analysis. *PLoS ONE*. 2012;7:e45493.
 44. Ruers T, Van Coevorden F, Punt CJA, et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. *Journal of the National Cancer Institute*. 2017;109:djx015.
 45. Starzl TE. The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955-1967). *Journal of the American College of Surgeons*. 2002;195:587–610.
 46. Moris D, Tsilimigras DI, Chakedis J, et al. Liver transplantation for unresectable colorectal liver metastases: A systematic review. *Journal of Surgical Oncology*. 2017;116:288–297.
 47. Dueland S, Syversveen T, Solheim JM, et al. Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases. *Annals of Surgery*. 2019;XX:XX.
 48. Morris EJA, Forman D, Thomas JD, et al. Surgical management and outcomes of colorectal cancer liver metastases. *British Journal of*

- Surgery*. 2010;97:1110–1118.
49. Raoof M, Haye S, Ituarte PHG, et al. Liver Resection Improves Survival in Colorectal Cancer Patients Causal-effects From Population-level Instrumental Variable Analysis. *Annals of surgery*. 2019;270:573–584.
 50. Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: Review and meta-analysis of prognostic factors. *Clinical Epidemiology*. 2012;4:283–301.
 51. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. *Annals of surgery*. 1999;230:309–18; discussion 318-21.
 52. Sasaki K, Morioka D, Conci S, et al. The Tumor Burden Score: A New “metro-ticket” Prognostic Tool for Colorectal Liver Metastases Based on Tumor Size and Number of Tumors. *Annals of Surgery*. 2018;267:132–141.
 53. Roberts KJ, White A, Cockbain A, et al. Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases. *British Journal of Surgery*. 2014;101:856–866.
 54. Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS). *Surgery*. 2011;149:713–724.
 55. Seyama Y, Kokudo N. Assessment of liver function for safe hepatic resection. *Hepatology Research*. 2009;39:107–116.
 56. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. *British Journal of Surgery*. 1973;60:646–649.
 57. Schroeder RA, Marroquin CE, Bute BP, et al. Predictive indices of morbidity and mortality after liver resection. *Annals of Surgery*. 2006;243:373–379.
 58. Bohte AE, van Werven JR, Bipat S, et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. *European radiology*. 2011;21:87–97.
 59. Kishi Y, Abdalla EK, Chun YS, et al. Three hundred and one consecutive extended right hepatectomies: Evaluation of outcome

- based on systematic liver volumetry. *Annals of Surgery*. 2009;250:540–547.
60. Kawaguchi Y, Lillemoe HA, Vauthey JN. Dealing with an insufficient future liver remnant: Portal vein embolization and two-stage hepatectomy. *Journal of Surgical Oncology*. 2019;119:594–603.
 61. Truant S, Oberlin O, Sergent G, et al. Remnant Liver Volume to Body Weight Ratio $\geq 0.5\%$: A New Cut-Off to Estimate Postoperative Risks after Extended Resection in Noncirrhotic Liver. *Journal of the American College of Surgeons*. 2007;204:22–33.
 62. Johnson TN, Tucker GT, Tanner MS, et al. Changes in liver volume from birth to adulthood: A meta-analysis. *Liver Transplantation*. 2005;11:1481–1493.
 63. Smith-Bindman R, Miglioretti DL, Larson EB. Rising use of diagnostic medical imaging in a large integrated health system. *Health Affairs*. 2008;27:1491–1502.
 64. Hori M, Suzuki K, Epstein ML, et al. Computed tomography liver volumetry using 3-dimensional image data in living donor liver transplantation: Effects of the slice thickness on the volume calculation. *Liver Transplantation*. 2011;17:1427–1436.
 65. Niehues S, Unger J, Malinowski M, et al. Liver volume measurement: reason of the difference between in vivo CT-volumetry and intraoperative ex vivo determination and how to cope it. *European Journal of Medical Research*. 2010;15:345.
 66. Sonnemans LJP, Ho JC, Monshouwer R, et al. Correlation between liver volumetric computed tomography results and measured liver weight: A tool for preoperative planning of liver transplant. *Experimental and Clinical Transplantation*. 2016;14:72–78.
 67. Vauthey J-NN, Abdalla EK, Doherty DA, et al. Body surface area and body weight predict total liver volume in western adults. *Liver Transplantation*. 2002;8:233–240.
 68. Taub R. Liver regeneration: From myth to mechanism. *Nature Reviews Molecular Cell Biology*. 2004;5:836–847.
 69. Higgins G, Anderson M. Experimental pathology of the liver. I. Restoration of the liver of the white rat following partial surgical removal. *Arch Pathol*. 1931;12:186–202.
 70. Overturf K, Al-Dhalimy M, Ou CN, et al. Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse

- hepatocytes. *The American journal of pathology*. 1997;151:1273–80.
71. Christophi C, Harun N, Fifis T. Liver regeneration and tumor stimulation-A review of cytokine and angiogenic factors. *Journal of Gastrointestinal Surgery*. 2008;12:966–980.
 72. Tanaka W, Yamanaka N, Oriyama T, et al. Multivariate analysis of liver regenerative capacity after hepatectomy in humans. *Journal of Hepato-Biliary-Pancreatic Surgery*. 1997;4:78–82.
 73. Tanaka K, Shimada H, Matsuo K, et al. Regeneration after two-stage hepatectomy vs repeat resection for colorectal metastasis recurrence. *Journal of Gastrointestinal Surgery*. 2007;11:1154–1161.
 74. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver. *Annals of Oncology*. 1999;663–669.
 75. Honjo I, Suzuki T, Ozawa K, et al. Ligation of a branch of the portal vein for carcinoma of the liver. *The American Journal of Surgery*. 1975;130:296–302.
 76. Schnitzbauer AA, Lang SA, Goessmann H, et al. Right Portal Vein Ligation Combined With In Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Stage Extended Right Hepatic Resection in Small-for-Size Settings. *Annals of Surgery*. 2012;255:405–414.
 77. Adam R, Laurent A, Azoulay D, et al. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. *Annals of Surgery*. 2000;232:777–785.
 78. Moris D, Ronnekleiv-Kelly S, Kostakis ID, et al. Operative Results and Oncologic Outcomes of Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Versus Two-Stage Hepatectomy (TSH) in Patients with Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-Anal. *World Journal of Surgery*. 2018;42:806–815.
 79. Sandström P, Røsok BI, Sparrelid E, et al. ALPPS Improves Resectability Compared with Conventional Two-stage Hepatectomy in Patients with Advanced Colorectal Liver Metastasis: Results from a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial). *Annals of Surgery*. 2018;267:833–840.
 80. Mentha G, Majno PE, Andres A, et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before

- treatment of the colorectal primary. *British Journal of Surgery*. 2006;93:872–878.
81. Kelly ME, Spolverato G, Lê GN, et al. Synchronous colorectal liver metastasis: A network meta-analysis review comparing classical, combined, and liver-first surgical strategies. *Journal of Surgical Oncology*. 2015;111:341–351.
 82. Simmonds P, Primrose J, Colquitt J, et al. Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies. *British Journal of Cancer*. 2006;94:982–999.
 83. Adam R, Pascal G, Azoulay D, et al. Liver Resection for Colorectal Metastases: The Third Hepatectomy. *Annals of Surgery*. 2003;238:871–884.
 84. Wurster EF, Tenckhoff S, Probst P, et al. A systematic review and meta-analysis of the utility of repeated versus single hepatic resection for colorectal cancer liver metastases. *HPB*. 2017;19:491–497.
 85. Register-based research | Swedish National Data Service Available from: <https://snd.gu.se/en/data-management/register-based-research>. Accessed September 16, 2019.
 86. Kvalitetsregistrens historia - Nationella Kvalitetsregister Available from: http://kvalitetsregister.se/tjanster/omnationellakvalitetsregister/kvalitet_sregistrenshistoria.2013.html. Accessed September 18, 2019.
 87. Kodeda K, Nathanaelsson L, Jung B, et al. Population-based data from the Swedish Colon Cancer Registry. *British Journal of Surgery*. 2013;100:1100–1107.
 88. Cancer i lever och gallvägar, 2015 Available from: https://www.cancercentrum.se/globalassets/cancerdiagnoser/lever-och-galla/kvalitetsregister/sweliv_rapport_2015_final.pdf. 2015. Accessed September 17, 2019.
 89. Cancer i lever och gallvägar, 2019 Available from: www.rccvast.se. 2019. Accessed September 17, 2019.
 90. Gliklich RE, Dreyer NA LM. Registries for Evaluating Patient Outcomes: A User’s Guide [Internet]. 3rd edition. Rockville (MD): Agency for Healthcare Research and Quality (US) Available from: <https://www.ncbi.nlm.nih.gov/books/NBK208632/?report=classic>. 2014.
 91. Biondi-Zoccai G, Romagnoli E, Agostoni P, et al. Are propensity

- scores really superior to standard multivariable analysis? *Contemporary Clinical Trials*. 2011;32:731–740.
92. Brazauskas R, Logan BR. Observational Studies: Matching or Regression? *Biology of Blood and Marrow Transplantation*. 2016;22:557–563.
 93. Morris E, Treasure T. If a picture is worth a thousand words, take a good look at the picture: Survival after liver metastasectomy for colorectal cancer. *Cancer Epidemiology*. 2017;49:152–155.
 94. Berry DA, Ueno NT, Johnson MM, et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: Overview of six randomized trials. *Journal of Clinical Oncology*. 2011;29:3224–3231.
 95. Mosteller RD. Simplified Calculation of Body-Surface Area. *New England Journal of Medicine*. 1987;317:1098–1098.
 96. Welsh FKS, Chandrakumaran K, John TG, et al. Propensity score-matched outcomes analysis of the liver-first approach for synchronous colorectal liver metastases. *British Journal of Surgery*. 2016;103:600–606.
 97. Ayez N, Burger JWA, van der Pool AE, et al. Long-term results of the “liver first” approach in patients with locally advanced rectal cancer and synchronous liver metastases. *Diseases of the colon and rectum*. 2013;56:281–7.
 98. de Rosa A, Gomez D, Hossaini S, et al. Stage IV colorectal cancer: outcomes following the liver-first approach. *Journal of surgical oncology*. 2013;108:444–449.
 99. Sasaki K, Margonis GA, Andreatos N, et al. The prognostic utility of the “Tumor Burden Score” based on preoperative radiographic features of colorectal liver metastases. *Journal of Surgical Oncology*. 2017;116:515–523.
 100. Wicherts DA, De Haas RJ, Salloum C, et al. Repeat hepatectomy for recurrent colorectal metastases. *British Journal of Surgery*. 2013;100:808–818.
 101. Muratore A, Polastri R, Bouzari H, et al. Repeat hepatectomy for colorectal liver metastases: A worthwhile operation? *Journal of Surgical Oncology*. 2001;76:127–132.
 102. HILL AB. THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION? *Proceedings of the Royal Society of Medicine*.

1965;58:295–300.

103. Stuart EA. Matching methods for causal inference: A review and a look forward. *Statistical Science*. 2010;25:1–21.